<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002977.pub2" GROUP_ID="NEONATAL" ID="925900092622504570" MERGED_FROM="" MODIFIED="2008-08-13 22:41:14 +0200" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Do not remove&lt;/p&gt;&lt;p&gt;CL 4/02&lt;/p&gt;&lt;p&gt;sent 10/05&lt;/p&gt;&lt;p&gt;CL 1/08 (substantive update)&lt;/p&gt;" NOTES_MODIFIED="2008-08-13 16:40:05 -0400" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="1" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-08-13 22:41:14 +0200" MODIFIED_BY="Diane Haughton">
<TITLE>Devices and pressure sources for administration of nasal continuous positive airway pressure (NCPAP) in preterm neonates</TITLE>
<CONTACT MODIFIED="2008-08-13 22:41:14 +0200" MODIFIED_BY="Diane Haughton"><PERSON ID="6C6D419F82E26AA201AA8B42EEDD0B93" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Antonio</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>De Paoli</LAST_NAME><SUFFIX>FRACP</SUFFIX><POSITION>Neonatologist</POSITION><EMAIL_1>antonio.depaoli@dhhs.tas.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatrics</DEPARTMENT><ORGANISATION>Royal Hobart Hospital</ORGANISATION><ADDRESS_1>Department of Paediatrics, Royal Hobart Hospital</ADDRESS_1><ADDRESS_2>GPO Box 1061</ADDRESS_2><CITY>Hobart</CITY><ZIP>7001</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 62227946</PHONE_1><PHONE_2>+61 419 117016</PHONE_2><FAX_1>+61 3 62264864</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-08-13 22:41:14 +0200" MODIFIED_BY="Diane Haughton"><PERSON ID="6C6D419F82E26AA201AA8B42EEDD0B93" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Antonio</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>De Paoli</LAST_NAME><SUFFIX>FRACP</SUFFIX><POSITION>Neonatologist</POSITION><EMAIL_1>antonio.depaoli@dhhs.tas.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatrics</DEPARTMENT><ORGANISATION>Royal Hobart Hospital</ORGANISATION><ADDRESS_1>Department of Paediatrics, Royal Hobart Hospital</ADDRESS_1><ADDRESS_2>GPO Box 1061</ADDRESS_2><CITY>Hobart</CITY><ZIP>7001</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 62227946</PHONE_1><PHONE_2>+61 419 117016</PHONE_2><FAX_1>+61 3 62264864</FAX_1></ADDRESS></PERSON><PERSON ID="17716" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Davis</LAST_NAME><EMAIL_1>pgd@unimelb.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>Royal Women's Hospital</ORGANISATION><ADDRESS_1>132 Grattan Street</ADDRESS_1><CITY>Carlton</CITY><ZIP>3053</ZIP><REGION>Victoria</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 93442151</PHONE_1><FAX_1>+61 3 93471761</FAX_1></ADDRESS></PERSON><PERSON ID="15212" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Brenda</FIRST_NAME><LAST_NAME>Faber</LAST_NAME><EMAIL_1>b.faber@obgyn-rwh.unimelb.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>Royal Women's Hospital</ORGANISATION><ADDRESS_1>132 Grattan Street</ADDRESS_1><CITY>Carlton</CITY><ZIP>3053</ZIP><REGION>Victoria</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 93442151</PHONE_1><FAX_1>+61 3 93471761</FAX_1></ADDRESS></PERSON><PERSON ID="15287" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Colin</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Morley</LAST_NAME><SUFFIX>MA DCH MD FRCP FRCPCH FRACP</SUFFIX><EMAIL_1>colin.morley@thewomens.org.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology </DEPARTMENT><ORGANISATION>Royal Women's Hospital</ORGANISATION><ADDRESS_1>132 Grattan Street</ADDRESS_1><CITY>Carlton</CITY><REGION>Victoria</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 3 9344 2335</PHONE_1><FAX_1>61 3 9347 2731</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-08-13 16:36:28 -0400" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;New studies found but not yet included or excluded: 31/05/07&lt;/p&gt;" NOTES_MODIFIED="2008-08-13 16:36:28 -0400" NOTES_MODIFIED_BY="Diane Haughton">
<UP_TO_DATE>
<DATE DAY="31" MONTH="8" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="5" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="8" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2008-05-30 13:22:16 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;br&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-05-30 13:22:16 -0400" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="30" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-08-13 16:40:05 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-08-13 16:39:53 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>This updates the review "Devices and pressure sources for administration of nasal continuous positive airway pressure (NCPAP) in preterm neonates" published in The Cochrane Library, Issue 4, 2002 (<LINK REF="REF-De-Paoli-2002" TYPE="REFERENCE">De Paoli 2002</LINK>).<BR/>
<BR/>An updated search identified three new trials for inclusion in this update (<LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK>; <LINK REF="STD-Rego-2002" TYPE="STUDY">Rego 2002</LINK>; <LINK REF="STD-Buettiker-2004" TYPE="STUDY">Buettiker 2004</LINK>).<BR/>
<BR/>Several additional trials were identified, but not eligible for inclusion and have been added to the Excluded Studies reference list.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Royal Women's Hospital Foundation, Melbourne</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Division of Research and Education, Royal Women's Hospital, Melbourne</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Murdoch Children's Research Institute, Melbourne</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Melbourne</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-05-30 13:23:30 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-05-30 13:23:09 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-05-30 13:23:07 -0400" MODIFIED_BY="[Empty name]">Devices and pressure sources for administration of nasal continuous positive airway pressure (NCPAP) in preterm neonates</TITLE>
<SUMMARY_BODY MODIFIED="2008-05-30 13:23:09 -0400" MODIFIED_BY="[Empty name]">
<P>After weaning preterm babies from a ventilator, short binasal prong devices for NCPAP (nasal continuous positive airways pressure) are more effective than single prong devices. Nasal continuous positive airway pressure (NCPAP) is a form of breathing support that is less invasive than mechanical ventilation (where a tube goes down into a baby's lungs). NCPAP usually delivers oxygen to a baby through tubes into the nose, or less commonly, through face masks. It can be used after weaning a baby from ventilation (extubation), or to help babies who need help for lung problems, but do not need ventilation. The review of trials found that short binasal prongs (entering both nostrils) are better than single prong NCPAP for preterm babies. More research is needed on the best pressure delivery system and the best pressure levels to use.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Nasal continuous positive airway pressure (NCPAP) is used to support preterm infants recently extubated, those experiencing significant apnoea of prematurity and those with respiratory distress soon after birth as an alternative to intubation and ventilation. This review focuses exclusively on identifying the most effective pressure source and interface for NCPAP delivery in preterm infants.<BR/> </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine which technique of pressure generation and which type of nasal interface for NCPAP delivery most effectively reduces the need for additional respiratory support in preterm infants extubated to NCPAP following intermittent positive pressure ventilation (IPPV) for respiratory distress syndrome (RDS) or in those treated with NCPAP soon after birth.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The strategy included searches of MEDLINE (1966 - 2006), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 4, 2006) CINAHL, abstracts from conference proceedings, cross-referencing of previous reviews and the use of expert informants. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised or quasi-randomised trials comparing different techniques of NCPAP pressure generation and/or nasal interfaces in preterm infants extubated to NCPAP following IPPV for RDS or treated with NCPAP soon after birth.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data was extracted and analysed by the first three authors. Dichotomous results were analysed using the relative risk (RR), risk difference (RD) and number needed to treat (NNT).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>1. Preterm infants being extubated to NCPAP following a period of IPPV for RDS:</P>
<P>Meta-analysis of the results from Davis 2001 and Roukema 1999a demonstrated that short binasal prongs are more effective at preventing re-intubation than single nasal or nasopharyngeal prongs [typical RR 0.59 (CI: 0.41, 0.85), typical RD -0.21 (CI: -0.35, -0.07), NNT 5 (CI: 3, 14)]. In one study comparing short binasal prong devices (Sun 1999), the re-intubation rate was significantly lower with the Infant Flow Driver than with the Medicorp prong [RR 0.33 (CI: 0.17, 0.67), RD -0.32 (CI: -0.49, -0.15), NNT 3 (CI: 2, 7)]. The other study comparing short binasal prong devices (Infant Flow Driver versus INCA prongs, Stefanescu 2003) demonstrated no significant difference in the re-intubation rate but did show a significant reduction in the total days in hospital in the Infant Flow Driver group [MD -12.60 (95% CI: -22.81, -2.39) days].<BR/> <BR/>2. Preterm infants primarily treated with NCPAP soon after birth:</P>
<P>In the one trial identified, Mazzella 2001 found a significantly lower oxygen requirement and respiratory rate in those randomised to short binasal prongs when compared with CPAP delivered via nasopharyngeal prong. The requirement for intubation beyond 48 hours from randomisation was not assessed.</P>
<P>3. Studies randomising preterm infants to different NCPAP systems using broad inclusion criteria</P>
<P>The studies of Rego 2002 and Buettiker 2004 did not examine the primary outcomes of this review. Of the secondary outcomes, Rego 2002 demonstrated a significantly higher incidence of nasal hyperaemia with the use of the Argyle prong compared with Hudson prongs [RR 2.39 (95% CI: 1.27, 4.50), RD 0.28 (95% CI: 0.10, 0.46)].</P>
<P>One study comparing different techniques of pressure generation is awaiting further assessment as it is currently available in abstract form only.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Short binasal prong devices are more effective than single prongs in reducing the rate of re-intubation. Although the Infant Flow Driver appears more effective than Medicorp prongs the most effective short binasal prong device remains to be determined. The improvement in respiratory parameters with short binasal prongs suggests they are more effective than nasopharyngeal CPAP in the treatment of early RDS. Further studies incorporating longer-term outcomes are required. Studies are also needed to determine the optimal pressure source for the delivery of NCPAP.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-05-30 13:23:30 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-05-30 13:23:29 -0400" MODIFIED_BY="[Empty name]">
<P>Nasal continuous positive airway pressure (NCPAP) is used widely to provide respiratory support for preterm neonates. In physiological terms NCPAP has been shown to:<BR/>1. increase functional residual capacity (<LINK REF="REF-Richardson-1978" TYPE="REFERENCE">Richardson 1978</LINK>) and improve oxygenation (<LINK REF="REF-Krouskop-1975" TYPE="REFERENCE">Krouskop 1975</LINK>; <LINK REF="REF-Harris-1976" TYPE="REFERENCE">Harris 1976</LINK>; <LINK REF="REF-Yu-1977" TYPE="REFERENCE">Yu 1977</LINK>),<BR/>2. dilate the larynx (<LINK REF="REF-Gaon-1999" TYPE="REFERENCE">Gaon 1999</LINK>), reduce supraglottic airway resistance (<LINK REF="REF-Miller-1990" TYPE="REFERENCE">Miller 1990</LINK>) and lessen the incidence of obstructive apnoea (<LINK REF="REF-Miller-1985" TYPE="REFERENCE">Miller 1985</LINK>),<BR/>3. improve the synchrony of respiratory thoracoabdominal movements (<LINK REF="REF-Locke-1991" TYPE="REFERENCE">Locke 1991</LINK>) and<BR/>4. enhance the Hering-Breuer inflation reflex following airway occlusion (<LINK REF="REF-Martin-1977" TYPE="REFERENCE">Martin 1977</LINK>).</P>
<P>NCPAP is clinically effective in the post-extubation period; however, the optimal method of administration is an area requiring further research (<LINK REF="REF-Davis-2000" TYPE="REFERENCE">Davis 2000</LINK>). NCPAP is also an alternative to intubation and mechanical ventilation for the support of preterm neonates with respiratory distress soon after birth. However, a systematic review found insufficient evidence to provide recommendations for its application in this clinical setting (<LINK REF="REF-Subramaniam-2000" TYPE="REFERENCE">Subramaniam 2000</LINK>).</P>
<P>CPAP has been applied to preterm infants using an array of devices. Its first application to the preterm neonate with respiratory distress was via an endotracheal tube or by enclosure of the head in a plastic pressure chamber (<LINK REF="REF-Gregory-1971" TYPE="REFERENCE">Gregory 1971</LINK>). Subsequent CPAP devices included a pressurised plastic bag fitted over the infant's head (<LINK REF="REF-Barrie-1972" TYPE="REFERENCE">Barrie 1972</LINK>), face chambers (<LINK REF="REF-Ahlstrom-1973" TYPE="REFERENCE">Ahlstrom 1973</LINK>) and face masks (<LINK REF="REF-Harris-1972" TYPE="REFERENCE">Harris 1972</LINK>; <LINK REF="REF-Rhodes-1973" TYPE="REFERENCE">Rhodes 1973</LINK>; <LINK REF="REF-Ackerman-1974" TYPE="REFERENCE">Ackerman 1974</LINK>). The use of tight-fitting facial masks and devices requiring a neck seal declined as a consequence of serious complications associated with their application, including an increased incidence of cerebellar haemorrhage (<LINK REF="REF-Pape-1976" TYPE="REFERENCE">Pape 1976</LINK>) and post-haemorrhagic hydrocephalus (<LINK REF="REF-Vert-1973" TYPE="REFERENCE">Vert 1973</LINK>). Nasal devices remained popular, as they facilitated better access to the infants (<LINK REF="REF-Chernick-1973" TYPE="REFERENCE">Chernick 1973</LINK>). Given the infrequent use of other methods of CPAP in current clinical practice, this review will focus exclusively on nasal interfaces and modes of pressure generation used in NCPAP delivery.</P>
<P>NASAL INTERFACES</P>
<P>Nasal masks, nasal cannulae, and single and binasal tubes/prongs of varying lengths, ending at either the nasal or nasopharyngeal level, have been developed.</P>
<UL>
<LI>Nasal masks</LI>
</UL>
<P>An early means of applying CPAP to neonates (<LINK REF="REF-Chernick-1973" TYPE="REFERENCE">Chernick 1973</LINK>; <LINK REF="REF-Cox-1974" TYPE="REFERENCE">Cox 1974</LINK>), nasal masks lost popularity because of the difficulty in maintaining an adequate seal and a tendency to cause nasal airway obstruction (<LINK REF="REF-Kattwinkel-1973" TYPE="REFERENCE">Kattwinkel 1973</LINK>). Although new masks have been developed and are in clinical use, they have not been subjected to comparison with other devices.</P>
<UL>
<LI>Single prong</LI>
</UL>
<P>Single prong CPAP, either nasopharyngeal or short nasal, is a relatively simple technique (<LINK REF="STD-Ahluwalia-1998" TYPE="STUDY">Ahluwalia 1998</LINK>). Single prong CPAP continues to be widely used despite a criticism of inefficiency (<LINK REF="REF-Field-1985" TYPE="REFERENCE">Field 1985</LINK>). The comparison of single with binasal prong interfaces comprises part of this review.</P>
<UL>
<LI>Binasal prongs</LI>
</UL>
<P>Binasal prongs, when introduced to deliver CPAP, proved simple, effective and safe to use, but had the potential to cause nasal trauma (<LINK REF="REF-Kattwinkel-1973" TYPE="REFERENCE">Kattwinkel 1973</LINK>; <LINK REF="REF-Agostino-1973" TYPE="REFERENCE">Agostino 1973</LINK>). A number of binasal devices are now in use including Argyle prongs (<LINK REF="REF-Kamper-1990" TYPE="REFERENCE">Kamper 1990</LINK>), Hudson prongs (<LINK REF="REF-Wung-1975" TYPE="REFERENCE">Wung 1975</LINK>; <LINK REF="REF-So-1992" TYPE="REFERENCE">So 1992</LINK>) and INCA prongs (<LINK REF="STD-Courtney-2001" TYPE="STUDY">Courtney 2001</LINK>). With the realisation that binasal prongs might result in a significant increase in work of breathing (<LINK REF="REF-Goldman-1979" TYPE="REFERENCE">Goldman 1979</LINK>), efforts were directed at designing a nasal interface that would minimise this by reducing airway resistance and fluctuations in airway pressure (<LINK REF="REF-Moa-1988" TYPE="REFERENCE">Moa 1988</LINK>). The resultant short-pronged binasal devices, currently known as Infant Flow or Aladdin Generators (EME, UK), are engineered to allow sufficient flow to the infant on inspiration while minimising expiratory resistance. Work with lung models (<LINK REF="REF-Moa-1988" TYPE="REFERENCE">Moa 1988</LINK>; <LINK REF="REF-Klausner-1996" TYPE="REFERENCE">Klausner 1996</LINK>) and a small study on preterm neonates with minimal lung disease (<LINK REF="STD-Pandit-2001" TYPE="STUDY">Pandit 2001</LINK>) demonstrated a reduced work of breathing when compared with conventional devices. However, limited randomised cross-over (<LINK REF="STD-Ahluwalia-1998" TYPE="STUDY">Ahluwalia 1998</LINK>) and non-randomised (<LINK REF="STD-Kavvadia-2000" TYPE="STUDY">Kavvadia 2000</LINK>) clinical studies found no significant difference in short-term physiological parameters when comparing the Infant Flow system with single prong NCPAP.</P>
<UL>
<LI>Nasopharyngeal prongs</LI>
</UL>
<P>Prongs inserted to the nasopharyngeal level have been used to deliver CPAP since the 1970's (<LINK REF="REF-Novogroder-1973" TYPE="REFERENCE">Novogroder 1973</LINK>; <LINK REF="REF-Boros-1976" TYPE="REFERENCE">Boros 1976</LINK>). Nasopharyngeal prongs received early criticism because they were perceived to be poorly tolerated and difficult to insert when compared with short nasal tube insertion (<LINK REF="REF-Caliumi_x002d_Pell.-1974" TYPE="REFERENCE">Caliumi-Pell. 1974</LINK>). However, the use of nasopharyngeal tubes became established in clinical practice and featured in trials which examined both binasal (<LINK REF="REF-Higgins-1991" TYPE="REFERENCE">Higgins 1991</LINK>) and single (<LINK REF="REF-Annibale-1994" TYPE="REFERENCE">Annibale 1994</LINK>) forms.</P>
<UL>
<LI>Nasal cannulae</LI>
</UL>
<P>Nasal cannulae are most often used in neonates to deliver supplemental oxygen at low flows (&lt;0.5 L/min) with no intention of generating significant airway pressure. Despite their relatively small calibre, nasal cannulae with an outer diameter of 3 mm and flows up to 2 L/min were reported to increase intra-oesophageal pressure and reduce thoracoabdominal motion asynchrony (<LINK REF="REF-Locke-1993" TYPE="REFERENCE">Locke 1993</LINK>). CPAP via nasal cannulae (flow up to 2.5 L/min) has been reported to be comparable with conventional NCPAP via nasal prongs in the management of apnoea of prematurity (Sreenan 2000). Optimal flow settings, appropriate cannula size, the delivery of adequate humidification and the effect on important outcomes with this nasal interface require further research.</P>
<P>In common with naso-endotracheal tubes, NCPAP interfaces have the potential to cause nasal excoriation and scarring if inappropriately applied or infrequently monitored (<LINK REF="REF-Loftus-1994" TYPE="REFERENCE">Loftus 1994</LINK>; <LINK REF="REF-Robertson-1996" TYPE="REFERENCE">Robertson 1996</LINK>). It is not clear which NCPAP device is least likely to cause nasal trauma.</P>
<P>TECHNIQUES FOR PRESSURE GENERATION<BR/>
<BR/>Techniques for CPAP generation include:</P>
<UL>
<LI>Expiratory flow valve (e.g. ventilator)</LI>
</UL>
<P>The use of variable resistance valves on the expiratory limb of NCPAP circuits is a common method of generating pressure. This is usually achieved through the use of a ventilator.</P>
<UL>
<LI>Underwater tube 'bubble' CPAP (underwater expiratory resistance)</LI>
</UL>
<P>Underwater bubble CPAP remains in use since first devised in the early 1970's (<LINK REF="REF-Gregory-1971" TYPE="REFERENCE">Gregory 1971</LINK>). It is a simple and effective technique for generating pressure. A comparison of underwater bubble endotracheal (ET) CPAP with ventilator derived ETCPAP in preterm neonates suggested that the bubbling contributed to gas exchange (<LINK REF="REF-Lee-1998" TYPE="REFERENCE">Lee 1998</LINK>); however, this effect not been studied when applied via the nasal route.</P>
<UL>
<LI>Benveniste device (pressure generation at nasal level: gas jet device connected to nasal prong/s)</LI>
</UL>
<P>The Benveniste paediatric gas jet device first delivered CPAP to the neonate via a face mask or by endotracheal tube (<LINK REF="REF-Benveniste-1976" TYPE="REFERENCE">Benveniste 1976</LINK>). Subsequent study of this device for NCPAP demonstrated that a high gas flow of 14 L/minute was required to create a pressure of between 3 and 10.5 cm H<SUB>2</SUB>O in the oropharynx. No significant difference in oropharyngeal pressure was noted whether the flow was delivered by single or binasal tube (<LINK REF="REF-Pedersen-1994" TYPE="REFERENCE">Pedersen 1994</LINK>). The Benveniste jet device, in conjunction with a binasal tube (Argyle prong), has been described as a simple and effective NCPAP system for preterm infants (<LINK REF="REF-Kamper-1990" TYPE="REFERENCE">Kamper 1990</LINK>).</P>
<UL>
<LI>Infant Flow Driver (IFD) system (pressure generation in Infant Flow 'Generator' at nasal level: adapted directly to Infant Flow short binasal prongs)</LI>
</UL>
<P>The IFD system (EME, UK) has a conventional flow source with a manometer. Pressure in the system is created at the level of the nasal device ('Generator') to which short binasal prongs, specifically made by EME for this device, are attached. The pressure generated in this device is controlled directly by adjusting the flow. Owing to their design the IFD prongs cannot be connected to other CPAP pressure systems.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The two primary objectives for each group were to determine:</P>
<P>a) Which technique of pressure generation for the delivery of NCPAP most effectively reduces the need for additional respiratory support and,</P>
<P>b) Which type of NCPAP interface most effectively reduces the need for additional respiratory support?</P>
<P>The two groups to be investigated were:</P>
<P>1. Preterm infants extubated to NCPAP following a period of intermittent positive pressure ventilation (IPPV) for respiratory distress syndrome (RDS) and,</P>
<P>2. Preterm infants initially treated with NCPAP soon after birth, either prophylactically or as treatment for RDS.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Only randomised and quasi-randomised studies were included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>1. Preterm infants (&lt;37 weeks gestation) extubated to NCPAP following a period of intermittent positive pressure ventilation (IPPV) for respiratory distress syndrome. Infants were intubated and ventilated at the time of study entry.</P>
<P>2. Preterm infants (&lt;37 weeks gestation) initially treated with NCPAP soon after birth, either prophylactically or as treatment for respiratory distress syndrome. NCPAP treatment was begun within 24 hours of birth.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Interventions in each group of participants were to comprise:</P>
<P>a) A comparison of the following techniques of pressure generation for the delivery of NCPAP: <BR/> <BR/>i) Underwater bubble NCPAP vs. NCPAP delivered by ventilator<BR/>ii) Underwater bubble NCPAP vs. NCPAP delivered by Benveniste device <BR/>iii) NCPAP delivered by ventilator vs. NCPAP delivered by Benveniste device</P>
<P>b) A comparison of NCPAP interfaces categorised as: </P>
<P>i) Short single vs. short binasal (double) prongs (nasal cannulae, Hudson prongs, Argyle prongs, IFD devices, INCA prongs or other double nasal prong interfaces) ii) Any short binasal prong vs. any other short binasal prong<BR/>iii) Single nasal (short) vs. long (nasopharyngeal) prongs<BR/>iv) Short binasal vs. long prongs<BR/>v) Single nasal or long prong vs. short binasal prongs*</P>
<P>Comparisons conducted after review of available data, i.e. not included in the published protocol, are asterixed (*). </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Primary outcome for both groups of participants:</P>
<P>The proportion requiring additional respiratory support either by endotracheal intubation and IPPV or nasal intermittent positive pressure ventilation (NIPPV) within a period of 7 days* following randomisation. </P>
<P>Secondary outcomes for both groups of participants:</P>
<P>a) Symptoms of respiratory failure*<BR/>b) 'Rescue' by alternate NCPAP device or mode of pressure generation*<BR/>c) Chronic lung disease incidence by comparison of: <BR/>
</P>
<UL>
<LI>supplemental oxygen requirement at 28 days of life</LI>
<LI>supplemental oxygen requirement at 36 weeks postmenstrual age </LI>
<LI>requirement for home oxygen therapy</LI>
</UL>
<P>d) Incidence of air leak following randomisation: pneumothorax, pulmonary interstitial emphysema, pneumomediastinum<BR/>e) Incidence of apnoea and bradycardia expressed as events per hour<BR/>f) Effectiveness of gas exchange by comparison of mean: <BR/>
</P>
<UL>
<LI>arterial or capillary pH </LI>
<LI>arterial, capillary or transcutaneous oxygen and carbon dioxide partial pressures </LI>
<LI>oxygen saturation and fraction of inspired oxygen</LI>
<LI>respiratory rate*</LI>
</UL>
<P>g) Total duration of NCPAP or endotracheal intubation in days<BR/>h) Rates of gastrointestinal complications: <BR/>
</P>
<UL>
<LI>necrotising enterocolitis (NEC) </LI>
<LI>gastrointestinal perforation </LI>
<LI>feeding intolerance as determined by days to establish enteral feeds of 150 mls/kg/day</LI>
<LI>feeding intolerance as defined by large or bilious gastric aspirates* </LI>
<LI>abdominal distension resulting in cessation of enteral feeding</LI>
</UL>
<P>i) Weight gain: <BR/>
</P>
<UL>
<LI>time to regain birth weight</LI>
<LI>weight at 28 days of life</LI>
<LI>weight gain from extubation to discharge*</LI>
<LI>weight gain in the week post-extubation*</LI>
</UL>
<P>j) Rate of sepsis: culture positive and suspected<BR/>k) Incidence of intraventricular haemorrhage (IVH) and periventricular leukomalacia (PVL) identified post-randomisation<BR/>l) Incidence of retinopathy of prematurity (ROP)<BR/>m) Long-term neurosensory outcomes at 2 years corrected age or older as defined by the incidence of:<BR/>
</P>
<UL>
<LI>cerebral palsy </LI>
<LI>moderate to severe developmental delay </LI>
<LI>blindness </LI>
<LI>deafness</LI>
</UL>
<P>n) Mortality<BR/>o) Utilisation of resources as defined by days in hospital and total days in oxygen (see (g) above for days of ventilation and NCPAP)</P>
<P>Subgroup analysis was planned according to trials using, or not using, methylxanthines to determine the impact of methylxanthine use on these outcomes. Additional subgroup analysis based on participant characteristics (e.g. stratification on birth weight or gestational age at intervention) was planned if appropriate. The subgroup of trials randomising to different NCPAP interfaces was also planned, to determine the incidence of nasal scarring.</P>
<P>A sensitivity analysis including only true randomised trials was planned if quasi-randomised trials were identified.</P>
<P>Outcome measures not specified a priori (included or modified after review of the available trials) are asterixed (*).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>The standard search strategy of the Neonatal Review Group of the Cochrane Collaboration was used. MEDLINE (1966 - December 2006) was searched using the MeSH terms: infant, newborn (exp) and positive-pressure respiration (exp) with keywords/phrases: continuous positive airway pressure or continuous distending pressure. The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 4, 2006) and CINAHL were also searched. Language restrictions were not applied. Abstracts published by the Society for Pediatric Research and the European Society for Pediatric Research were searched for the period 1996 to 2006. Cross referencing of previous reviews and expert informants were also used. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>The standard method of the Cochrane Collaboration and its Neonatal Review Group was used. Trial searching, methodologic assessment and data extraction were performed independently by the first three authors before comparison and resolution of differences at each stage. Methodology was assessed by adequacy of blinding of randomisation, blinding of intervention, completeness of follow-up and blinding of outcome measurement. The authors were contacted for further information for completeness of data or study methodology. Additional unpublished data were supplied by Drs Sun (results for the outcomes: 'Death', 'Chronic lung disease', 'Air leak', 'Sepsis', 'NEC' and 'Days of respiratory support') and Davis (results for the outcome: 'NEC', and means and standard deviations for the outcomes: 'Days of respiratory support' and 'Days in level III hospital').</P>
<P>Categorical data (e.g. number requiring additional respiratory support) were analysed using relative risk (RR), risk difference (RD) and number needed to treat (NNT). Meta-analysis of continuous data (e.g. number of days of CPAP) was to be performed with the weighted mean difference (WMD) using the fixed effect model. Confidence intervals of 95% were adopted.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-05-30 13:23:30 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-05-30 13:23:29 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>
<BR/>1. Preterm infants extubated to NCPAP following a period of IPPV for RDS</B>
</P>
<P>Four studies (<LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK>; <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK>; <LINK REF="STD-Roukema-1999a" TYPE="STUDY">Roukema 1999a</LINK> and <LINK REF="STD-Sun-1999" TYPE="STUDY">Sun 1999</LINK>) that compared different NCPAP devices in the period following endotracheal intubation and ventilation for RDS were identified for inclusion. The studies of <LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK> (162 infants) and <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK> (87 infants) were available as a full journal publications, whereas the studies of <LINK REF="STD-Roukema-1999a" TYPE="STUDY">Roukema 1999a</LINK> (93 infants) and <LINK REF="STD-Sun-1999" TYPE="STUDY">Sun 1999</LINK> (100 infants) remain available in abstract form only. The study by <LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK> could also be considered in the category of studies comparing different methods of NCPAP pressure generation. It is included in the comparison of different nasal interfaces ('Any short binasal prong vs. any other short binasal prong') as the different nasal interfaces used were considered the main point of difference between the two systems compared in this trial. Details of these studies are included in the table 'Characteristics of Included Studies'.<BR/>
<BR/>All four studies randomised intubated, very low birth weight, preterm infants at the time of extubation. Detailed extubation criteria are available only for <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK>; <LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK> and <LINK REF="STD-Sun-1999" TYPE="STUDY">Sun 1999</LINK> (low ventilatory requirements). Details of methylxanthine usage are only available for <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK>, where all infants were loaded with theophylline at the time of extubation, and <LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK>, where the study protocol mandated universal methylxanthine treatment prior to extubation.<BR/>
<BR/>The NCPAP interventions in each study were:<BR/>
</P>
<UL>
<LI>
<LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK> randomised infants to either Infant Flow Driver (short binasal prongs) or INCA prongs (short binasal prongs)</LI>
<LI>
<LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK> randomised infants to either single prong or to binasal (Hudson) prong NCPAP</LI>
<LI>
<LINK REF="STD-Sun-1999" TYPE="STUDY">Sun 1999</LINK> randomised infants to NCPAP via Medicorp prongs (short binasal prongs) or Infant Flow Driver (short binasal prongs)</LI>
<LI>
<LINK REF="STD-Roukema-1999a" TYPE="STUDY">Roukema 1999a</LINK> randomised infants to NCPAP via nasopharyngeal prong or Infant Flow Driver</LI>
</UL>
<P>
<BR/>The initial NCPAP pressure settings are known for the studies of <LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK> (4-6 cmH<SUB>2</SUB>O), <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK> (7 cmH<SUB>2</SUB>O) and <LINK REF="STD-Sun-1999" TYPE="STUDY">Sun 1999</LINK> (5 cmH<SUB>2</SUB>O). The initial set NCPAP flow is known only for the study of <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK> (6 L/min). The starting pressure and flow settings were the same for both treatment arms in these studies.</P>
<P>
<LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK> and <LINK REF="STD-Sun-1999" TYPE="STUDY">Sun 1999</LINK> defined their primary outcome as meeting respiratory failure criteria within the seven days following extubation. The decision to re-intubate in <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK> was at the discretion of the attending physician, whereas re-intubation was performed in <LINK REF="STD-Sun-1999" TYPE="STUDY">Sun 1999</LINK> if the pre-determined failure criteria were met. For <LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK> and <LINK REF="STD-Roukema-1999a" TYPE="STUDY">Roukema 1999a</LINK> the primary outcome was defined as remaining extubated in the seven days post-extubation. Crossover to, or 'rescue' by the alternative mode of NCPAP was not permitted by any study.</P>
<P>
<B>2. Preterm infants initially treated with NCPAP soon after birth, either prophylactically or as treatment for RDS</B>
</P>
<P>
<LINK REF="STD-Mazzella-2001" TYPE="STUDY">Mazzella 2001</LINK> was the only study published in full that randomised only preterm neonates with early RDS to different NCPAP devices. Infants of less than 36 weeks' gestation with RDS at less than 12 hours of age were randomly allocated to receive NCPAP either via single nasopharyngeal tube or via the Infant Flow system (short binasal prongs). These infants were on average more mature (32 - 33 weeks' gestation) than those enrolled in the studies comparing NCPAP devices in the post-extubation period (26 weeks' gestation). Those infants who had received antenatal corticosteroids or were intubated at delivery were excluded. The initial NCPAP pressure setting for both groups was 4 cmH<SUB>2</SUB>O, with the study protocol limiting the maximum pressure to 6 cmH<SUB>2</SUB>O. The set flow rates for nasopharyngeal CPAP, usually 4 to 7 L/min, were reported as being sufficient to meet an infant's inspiratory flow demand. For the Infant Flow system flows of 6 to 8 L/min were required to generate a pressure of 4 to 5 cmH<SUB>2</SUB>O at the device. Caffeine citrate was begun in each infant from the time of enrolment.</P>
<P>The primary outcome was change in the oxygen requirement and/or respiratory rate within 48 hours. Secondary outcomes included the success rate of weaning and complications including death, intraventricular haemorrhage, air leak and chronic lung disease.</P>
<P>Cross-over to the alternative mode of NCPAP or intubation for surfactant treatment could be considered if an infant met respiratory failure criteria.</P>
<P>
<B>3. Studies randomising preterm infants to different NCPAP systems using broad inclusion criteria</B>
</P>
<P>Two studies, <LINK REF="STD-Rego-2002" TYPE="STUDY">Rego 2002</LINK> and <LINK REF="STD-Buettiker-2004" TYPE="STUDY">Buettiker 2004</LINK>, randomised preterm infants to different NCPAP systems using inclusion criteria that resulted in significant heterogeneity in the clinical conditions of those randomised. Consequently, infants with early respiratory distress, infants requiring post-extubation support and infants with other indications for respiratory support were potentially eligible and were randomised. The infants in these studies were comparatively more mature than those included in the trials randomising infants only in the post-extubation setting.</P>
<P>
<LINK REF="STD-Rego-2002" TYPE="STUDY">Rego 2002</LINK> randomised a total of 71 neonates &#8804; 2500 g with RDS, transient tachypnoea of the newborn, apnoea of prematurity, pneumonia and those requiring post-extubation support. Infants were randomised to NCPAP delivered either by Argyle prongs or via Hudson prongs, with pressure in both groups generated by conventional ventilator. Analysis was by mode of NCPAP treatment, stratified by weight category (&#8804; 1000 g, 1000 to 1500 g, 1500 to 2500 g) but not by clinical inclusion criteria, thus rendering the study difficult to assess according to the <I>a priori</I> criteria of this review. The primary outcome was CPAP 'success' defined as avoiding intubation and weaning off CPAP without requiring recommencement of respiratory support in the 72 hours following cessation. This primary outcome does not meet the <I>a priori</I> requirements of this review however some of the secondary outcomes, including the incidence of air leak and nasal trauma, are applicable.</P>
<P>
<LINK REF="STD-Buettiker-2004" TYPE="STUDY">Buettiker 2004</LINK> randomised a total of 40 newborn infants with respiratory distress to three different NCPAP systems: Infant Flow NCPAP system, single prong nasopharyngeal CPAP and Hudson prong NCPAP. Only six out of a total of 20 patients in the strata with weight &gt; 2500 g were preterm infants and therefore this subgroup was not considered for analysis as the subjects did not meet the <I>a priori</I> inclusion criteria for this review. The strata of infants of weight 1250 to 2500 g (median 1790 g) were all preterm (&lt;37 weeks gestation) and hence could be considered for analysis. Inclusion criteria were heterogeneous with randomised infants in the 1250 to 2500 g (median 1790 g) strata requiring support for respiratory distress syndrome, post-extubation support (randomisation pre-extubation not specified), meconium aspiration syndrome, respiratory syncytial virus infection, neuromuscular disorders and necrotising enterocolitis. The primary outcomes of this study included the length of NCPAP treatment and the incidence of nasal trauma but did not encompass the <I>a</I> <I>priori</I> primary outcome of this review.</P>
<P>
<B>4. Studies awaiting further assessment</B>
</P>
<P>
<LINK REF="STD-Colaizy-2004" TYPE="STUDY">Colaizy 2004</LINK>: This study is currently published in abstract form only. Very low birth weight and preterm infants (&lt; 1500 g; 24 to 32 weeks gestation) with early RDS were randomised to NCPAP generated either via an underwater bubble system or via a conventional ventilator. Hudson prongs were used as the nasal interface in each arm of the trial. Each group was treated with a NCPAP pressure of 5 cmH<SUB>2</SUB>O. Outcomes included 'CPAP failures', 'CPAP complications', days of supplemental oxygen, days of mechanical ventilation, length of hospital stay, incidence of chronic lung disease and surfactant use. Further information on this study is required to allow further assessment and inclusion in this review.</P>
<P>None of the included studies examined long-term neurodevelopment as an outcome.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-05-30 13:23:30 -0400" MODIFIED_BY="[Empty name]">
<P>The criteria of the Neonatal Cochrane Review Group was used to assess methodological quality.</P>
<P>
<B>Allocation concealment</B>
<BR/>Allocation concealment was adequate for <LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK>; <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK>; <LINK REF="STD-Sun-1999" TYPE="STUDY">Sun 1999</LINK> and <LINK REF="STD-Mazzella-2001" TYPE="STUDY">Mazzella 2001</LINK>. <LINK REF="STD-Rego-2002" TYPE="STUDY">Rego 2002</LINK> randomised infants by drawing lots. Further information on allocation concealment is required on the studies of <LINK REF="STD-Roukema-1999a" TYPE="STUDY">Roukema 1999a</LINK> and <LINK REF="STD-Buettiker-2004" TYPE="STUDY">Buettiker 2004</LINK>.</P>
<P>
<B>Blinding of intervention</B>
<BR/>No study attempted to blind the intervention.</P>
<P>
<B>Completeness of follow-up</B>
<BR/>Adequate follow-up was accomplished in all trials except <LINK REF="STD-Rego-2002" TYPE="STUDY">Rego 2002</LINK> where three infants were excluded from analysis for complications as their time on NCPAP was less than two hours.</P>
<P>
<B>Blinding of outcome assessment</B>
<BR/>In the study by <LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK>, the radiologists assessing cranial ultrasounds were blinded to the treatment allocation. Blinding of outcome assessment was not attempted in any of the other trials.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-05-30 13:23:30 -0400" MODIFIED_BY="[Empty name]">
<P>A total of seven studies met inclusion criteria for the review. Four studies (<LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK>; <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK>; <LINK REF="STD-Roukema-1999a" TYPE="STUDY">Roukema 1999a</LINK> and <LINK REF="STD-Sun-1999" TYPE="STUDY">Sun 1999</LINK>) compared NCPAP interfaces in the prevention of extubation failure. One study (<LINK REF="STD-Mazzella-2001" TYPE="STUDY">Mazzella 2001</LINK>) compared NCPAP interfaces in the treatment of early respiratory distress. Two studies (<LINK REF="STD-Buettiker-2004" TYPE="STUDY">Buettiker 2004</LINK> and <LINK REF="STD-Rego-2002" TYPE="STUDY">Rego 2002</LINK>) compared different NCPAP devices for a mixed group of neonatal respiratory conditions. While the primary outcomes of <LINK REF="STD-Buettiker-2004" TYPE="STUDY">Buettiker 2004</LINK> and <LINK REF="STD-Rego-2002" TYPE="STUDY">Rego 2002</LINK> did not satisfy the a priori criteria of this review some of the secondary outcomes were relevant.</P>
<P>
<B>PRETERM INFANTS EXTUBATED TO NCPAP FOLLOWING A PERIOD OF IPPV</B>
</P>
<P>
<B>INFANT FLOW DRIVER (SHORT BINASAL) VS. INCA PRONG (SHORT BINASAL) NCPAP TO PREVENT EXTUBATION FAILURE (COMPARISON 05): </B>
<LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK>
</P>
<UL>
<LI>
<B>
<I>Endotracheal intubation within 7 days post-extubation (Outcome 05.01):</I>
</B>
</LI>
</UL>
<P>There was no significant difference in the rate of re-intubation between those randomised to Infant Flow Driver versus INCA prong NCPAP [RR 1.01 (95% CI: 0.68, 1.49), RD 0.00 (95% CI: -0.15, 0.15)].</P>
<UL>
<LI>
<B>
<I>Other outcomes (Outcomes 05.02 - 05.06):</I>
</B>
</LI>
</UL>
<P>Comparing infants randomised to the Infant Flow Driver versus the INCA prong there were no statistically significant differences in the outcomes of death [RR 2.87 (95% CI: 0.79, 10.44), RD 0.07 (95% CI: -0.01, 0.15) trend favouring INCA prong], chronic lung disease [at 36 weeks postmenstrual age, RR 0.86 (95% CI: 0.65, 1.14), RD -0.08 (95% CI: -0.24, 0.07)], grade 3 and 4 intraventricular haemorrhage [RR 0.85 (95% CI: 0.41, 1.75), RD -0.03 (95% CI: -0.14, 0.09)], periventricular leukomalacia, retinopathy of prematurity, air leak, sepsis and necrotising enterocolitis. However, in the Infant Flow Driver group there was a significantly lower duration of hospital stay [MD -12.60 (95% CI: -22.81, -2.39) days] and lower total days of supplemental oxygen [MD -11.50 (95% CI: -21.74, -1.26) days] when compared to the INCA prong group.</P>
<P>
<B>SHORT BINASAL PRONG VS. SINGLE NASAL PRONG CPAP TO PREVENT EXTUBATION FAILURE (Comparison 01):</B> <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK>
</P>
<UL>
<LI>
<B>
<I>Endotracheal intubation within 7 days post-extubation (Outcome 01.01.01):</I>
</B>
</LI>
</UL>
<P>A trend, not reaching statistical significance, favoured the use of short binasal prongs in preventing re-intubation [RR 0.53 (CI: 0.27, 1.04), RD -0.19 (CI: -0.38, 0.00)].<BR/>
<BR/>
</P>
<UL>
<LI>
<B>
<I>Respiratory failure within 7 days post-extubation (Outcome 01.01.02):</I>
</B>
</LI>
</UL>
<P>Infants extubated to NCPAP using short binasal prongs had a statistically and clinically significantly lower incidence of respiratory failure [RR 0.43 (CI: 0.24, 0.78), RD -0.32 (CI: -0.52, -0.13)]. Three (CI: 2, 8) infants would need to be treated with short binasal rather than single nasal prongs to avoid respiratory failure in one infant.</P>
<UL>
<LI>
<B>
<I>Other outcomes (Outcomes 01.02 - 01.07):</I>
</B>
</LI>
</UL>
<P>No statistically significant differences were found for rates of complications including death [RR 1.68 (CI: 0.30, 9.58), RD 0.03 (CI: -0.07, 0.13)], chronic lung disease [at 36 weeks postmenstrual age: RR 0.80 (CI: 0.54, 1.18), RD -0.12 (CI: -0.33, 0.09)], intraventricular haemorrhage [RR 1.68 (CI: 0.30, 9.58), RD 0.03 (CI: -0.07, 0.13)], retinopathy of prematurity, sepsis or feeding intolerance. Weight gain, both in the week post-extubation and to the time of discharge, was not significantly different between the two treatment arms. [See Comparison 01 tables: 'Death', 'Chronic lung disease', 'Non-pulmonary outcomes' (IVH, PVL, ROP, sepsis, feeding intolerance, NEC), 'Weight gain', 'Days of respiratory support' and 'Resource utilisation' (days in level III hospital)].</P>
<P>
<B>INFANT FLOW DRIVER (SHORT BINASAL) VS. MEDICORP PRONG (SHORT BINASAL) NCPAP TO PREVENT EXTUBATION FAILURE (Comparison 02): </B>
<LINK REF="STD-Sun-1999" TYPE="STUDY">Sun 1999</LINK>
</P>
<UL>
<LI>
<B>
<I>Endotracheal intubation within 7 days following extubation (Outcome 02.01):</I>
</B>
</LI>
</UL>
<P>Infants in both arms of this study were extubated to short binasal prongs. However, the likelihood of re-intubation in the week following extubation in those randomised to the Infant Flow Driver was lower at a statistically and clinically significant level [RR 0.33 (CI: 0.17, 0.67), RD -0.32 (CI: -0.49, -0.15), NNT 3 (CI: 2, 7)]. All those infants that met respiratory failure criteria were re-intubated.</P>
<UL>
<LI>
<B>
<I>Other outcomes (Outcomes 02.02 - 02.05):</I>
</B>
</LI>
</UL>
<P>No statistically significant differences were present for the outcomes of death (no deaths in either group), chronic lung disease [at 36 weeks postmenstrual age: RR 0.86 (CI: 0.31, 2.37), RD -0.02 (CI: -0.15, 0.11)], air leak, sepsis or necrotising enterocolitis. [See Comparison 02 tables: 'Death', 'Pulmonary outcomes' (chronic lung disease and air leak), 'Non-pulmonary outcomes' (sepsis and NEC), and 'Days of respiratory support'].</P>
<P>
<B>SHORT BINASAL PRONG (INFANT FLOW DRIVER) VS. NASOPHARYNGEAL PRONG CPAP TO PREVENT EXTUBATION FAILURE (COMPARISON 03):</B> <LINK REF="STD-Roukema-1999a" TYPE="STUDY">Roukema 1999a</LINK>
</P>
<UL>
<LI>
<B>
<I>Endotracheal intubation within 7 days following extubation (Outcome 03.01):</I>
</B>
</LI>
</UL>
<P>Those extubated to the short binasal prong (Infant Flow Driver) had a lower rate of re-intubation [RR 0.63 (CI: 0.40, 0.97), RD -0.23 (CI: -0.42, -0.03), NNT 4 (CI: 2, 33)] when compared with the nasopharyngeal prong group. This result is statistically and clinically significant.<BR/>
<BR/>
</P>
<UL>
<LI>
<B>
<I>Other outcomes</I> </B>
</LI>
</UL>
<P>Results for other outcomes are not yet available.</P>
<P>
<B>SHORT BINASAL PRONG VS. SINGLE PRONG (NASAL OR NASOPHARYNGEAL) NCPAP TO PREVENT EXTUBATION FAILURE (COMPARISON 04):</B> <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK> and <LINK REF="STD-Roukema-1999a" TYPE="STUDY">Roukema 1999a</LINK>
</P>
<UL>
<LI>
<B>
<I>Endotracheal intubation within 7 days following extubation (Outcome 04.01):</I>
</B>
</LI>
</UL>
<P>Meta-analysis of this outcome in the studies by <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK> and <LINK REF="STD-Roukema-1999a" TYPE="STUDY">Roukema 1999a</LINK> showed a statistically significant and clinically important benefit for those extubated to short binasal prongs [typical RR 0.59 (CI: 0.41, 0.85), typical RD -0.21 (CI: -0.35, -0.07), NNT 5 (CI: 3, 14)].<BR/>
<BR/>
</P>
<UL>
<LI>
<B>
<I>Other outcomes (Outcomes 04.02 - 04.07):</I>
</B>
</LI>
</UL>
<P>Meta-analysis of other outcomes will not be possible until results from the full publication of the study by <LINK REF="STD-Roukema-1999a" TYPE="STUDY">Roukema 1999a</LINK> are available. The available results in the remaining tables for Comparison 04 are as per Comparison 01 (<LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK>).</P>
<P>Subgroup analysis in these studies according to methylxanthine use is not possible. Methylxanthine use was universal in <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK> and almost universal in <LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK> (3 in the Infant Flow Driver group and 7 in the INCA prong group did not receive methylxanthine therapy pre-extubation) but is not yet known for <LINK REF="STD-Roukema-1999a" TYPE="STUDY">Roukema 1999a</LINK> or <LINK REF="STD-Sun-1999" TYPE="STUDY">Sun 1999</LINK>. No information on rates of nasal trauma is available for these trials.</P>
<P>
<B>PRETERM INFANTS INITIALLY TREATED WITH NCPAP SOON AFTER BIRTH, EITHER PROPHYLACTICALLY OR AS A TREATMENT FOR RDS<BR/>
</B>
<BR/>
<B>SHORT BINASAL PRONG VS. NASOPHARYNGEAL (SINGLE TUBE) CPAP FOR EARLY RESPIRATORY DISTRESS (COMPARISON 06):</B> <LINK REF="STD-Mazzella-2001" TYPE="STUDY">Mazzella 2001</LINK>
</P>
<UL>
<LI>
<B>
<I>Endotracheal intubation and respiratory failure within 7 days post-randomisation (Outcome 06.01):</I>
</B>
</LI>
</UL>
<P>These outcomes were not assessed beyond 48 hours from randomisation. There was no significant difference in these outcomes for this limited period.</P>
<UL>
<LI>
<B>
<I>Oxygen requirement and respiratory rate</I>
</B>
</LI>
</UL>
<P>The oxygen requirement and respiratory rate were significantly lower (p &lt; 0.0001, as calculated by <LINK REF="STD-Mazzella-2001" TYPE="STUDY">Mazzella 2001</LINK>) in the short binasal prong group over the 48 hours following randomisation. This outcome is not able to be represented as a mean difference as the study used univariate repeated measures analysis.</P>
<UL>
<LI>
<B>
<I>Other outcomes (Outcomes 06.02 - 06.05):</I>
</B>
</LI>
</UL>
<P>There were no cases of death, chronic lung disease or IVH in either group. No significant differences were found for the rates of pneumothorax or nasal trauma. [See Comparison 06 tables: 'Death', 'Pulmonary outcomes' (chronic lung disease and pneumothorax), 'Non-pulmonary outcomes' (IVH and nasal trauma), 'Total days of respiratory support'].</P>
<P>Subgroup analysis according to methylxanthine use was not possible as all infants in <LINK REF="STD-Mazzella-2001" TYPE="STUDY">Mazzella 2001</LINK> received caffeine citrate.</P>
<P>
<B>STUDIES RANDOMISING PRETERM INFANTS TO DIFFERENT NCPAP SYSTEMS USING BROAD INCLUSION CRITERIA</B>
</P>
<P>
<B>ARGYLE PRONG (SHORT BINASAL) VS. HUDSON PRONG (SHORT BINASAL) CPAP FOR PRETERM INFANTS REQUIRING RESPIRATORY SUPPORT (COMPARISON 07): </B>
<LINK REF="STD-Rego-2002" TYPE="STUDY">Rego 2002</LINK>
</P>
<UL>
<LI>
<B>
<I>Respiratory failure and endotracheal intubation within 7 days post-randomization for respiratory distress syndrome or post-extubation support</I>
</B>
</LI>
</UL>
<P>This outcome was not assessed in this study. The primary outcome assessed in this trial of successful weaning from NCPAP was not an <I>a priori </I>outcome of this review. NCPAP was considered to have failed in those patients who required intubation to receive surfactant at the attending clinician's discretion. It is not possible from the published results to determine the number of infants that were intubated in each clinical category (apnoea, respiratory distress syndrome, pneumonia, transient tachypnoea of the newborn and post-extubation support) or in each treatment arm (Argyle prong versus Hudson prong). It is also important to note that no respiratory failure or intubation criteria were specified. The absence of such criteria may lead to intervention bias as the clinicians are not blinded to the mode of NCPAP.</P>
<UL>
<LI>
<B>
<I>Other outcomes (Outcomes 07.01 - 07.02):</I>
</B>
</LI>
</UL>
<P>Infants randomised to Argyle prong NCPAP had a significantly higher incidence of nasal hyperaemia compared to those treated with Hudson prong NCPAP when the results of all weight categories are combined [RR 2.39 (95% CI: 1.27, 4.50), RD 0.28 (95% CI: 0.10, 0.46)]. When the authors analysed the incidence of nasal hyperaemia in each of the three weight strata (&#8804; 1000 g, 1000-1500 g, 1500-2500 g) the increase in nasal hyperaemia in the Argyle prong group only reached statistical significance for those infants in the &#8804; 1000 g subgroup. There was no significant difference in the incidence of nasal bleeding and there were no cases of nasal septum necrosis. The published results do not permit sub-analysis of the nasal trauma incidence according to the clinical category of the infants at the time of randomisation. There were no cases of pneumothorax in either arm of the study.<BR/>
<B>
<BR/>INFANT FLOW DRIVER (SHORT BINASAL) VS. HUDSON PRONG (SHORT BINASAL) VS. NASOPHARYNGEAL (SINGLE PRONG) CPAP FOR NEWBORN INFANTS REQUIRING RESPIRATORY SUPPORT</B> - <LINK REF="STD-Buettiker-2004" TYPE="STUDY">Buettiker 2004</LINK>
</P>
<P>The results for infants in the &gt; 2500 g weight strata were excluded as these infants were predominantly term.</P>
<UL>
<LI>
<B>
<I>Respiratory failure and endotracheal intubation within 7 days post-randomization for respiratory distress syndrome or post-extubation support</I>
</B>
</LI>
</UL>
<P>This was not the primary outcome for this trial. In the 1250 to 2500 g weight strata four infants required intubation (two for respiratory distress syndrome and two for neuromuscular disease). The results do not specify the NCPAP devices to which these four infants were randomised.</P>
<UL>
<LI>
<B>
<I>Other outcomes</I>
</B>
</LI>
</UL>
<P>The primary outcomes in this trial included the duration of nasal CPAP treatment and the frequency of nasal trauma. In the 1250 to 2500 g weight strata the overall median duration of CPAP was 1.1 (range 0.1 - 7) days with no significant difference between the three groups. Of the 20 infants in this stratum, 3 infants of 6 on Infant Flow Driver, 2 infants of 6 on Hudson prong and 2 infants of 8 on nasopharyngeal CPAP developed a nasal injury with no statistically significant difference between these groups.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-05-30 13:23:30 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>
<BR/>1. Preterm infants being extubated to NCPAP following a period of IPPV for RDS</B>
</P>
<P>The four included studies are methodologically sound, although further information is awaited on the study of <LINK REF="STD-Roukema-1999a" TYPE="STUDY">Roukema 1999a</LINK> on allocation concealment. As it is impractical to blind caregivers to the NCPAP intervention it is possible that bias in the use of co-interventions may have occurred. Only <LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK> and <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK> at present account for the use of methylxanthines. Criteria for respiratory failure and/or indications for intubation are clearly described in <LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK>; <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK> and <LINK REF="STD-Sun-1999" TYPE="STUDY">Sun 1999</LINK> reducing the potential for bias, however this information is not available for the study of <LINK REF="STD-Roukema-1999a" TYPE="STUDY">Roukema 1999a</LINK>.</P>
<P>Short binasal prong devices appear to be more effective than single prong devices in reducing both the symptoms of respiratory failure and the rate of re-intubation. It is likely that short binasal prongs are more effective at transmitting the prescribed pressure to the airway than single prong devices and as a result reduce the chances of respiratory failure. While the infant's own nasal airway has resistance to air flow, the passage of a nasopharyngeal prong through the nasal passage reduces the diameter of the airway and increases this resistance. Air-leak out through the contralateral nostril (which has no prong <I>in situ</I>) is likely to significantly diminish the applied pressure. Other outcomes such as chronic lung disease and gastrointestinal complications appear not to be influenced by device type. However, the numbers randomised to date are small and further data from completed trials is awaited.</P>
<P>In the direct comparisons of short binasal prong devices the Infant Flow Driver was shown to be more effective than Medicorp prongs (<LINK REF="STD-Sun-1999" TYPE="STUDY">Sun 1999</LINK>) at preventing re-intubation in the week post-extubation. This should not be extrapolated to the type of pressure generation (i.e. that the Infant Flow system is more effective than a ventilator at generating CPAP) as the result may be attributable to a higher resistance to flow in the Medicorp prong. The appearance of the Medicorp prong (personal communication with Dr Shyan Sun) closely resembles that of the Argyle prong which has a relatively higher resistance to flow compared to other types of double prong (<LINK REF="REF-De-Paoli-2002" TYPE="REFERENCE">De Paoli 2002</LINK>).</P>
<P>The trial of <LINK REF="STD-Stefanescu-2003" TYPE="STUDY">Stefanescu 2003</LINK> comparing the Infant Flow Driver with the INCA prong demonstrated that there was a significantly lower duration of hospital stay in the Infant Flow Driver group. However, there were no significant differences in other clinically important outcomes.</P>
<P>The design of the included studies did not permit a direct comparison of techniques of pressure generation. Although the structure of the Infant Flow binasal prong is such that it cannot be connected to other systems, a comparison of the Infant Flow system of pressure generation with another (e.g. ventilator or underwater bubbler) remains feasible. This can be achieved if the resistance of the binasal prongs to flow in each arm of the study (Infant Flow prongs have a low resistance) is comparable to allow equivalent transmission of pressure to the airway. The most effective and least traumatic short binasal device remains to be determined.</P>
<P>
<B>2. Preterm infants initially treated with NCPAP soon after birth, either prophylactically or as treatment for RDS</B>
</P>
<P>The single study comparing a nasopharyngeal with a short binasal prong in this population of infants (<LINK REF="STD-Mazzella-2001" TYPE="STUDY">Mazzella 2001</LINK>) was powered to detect significant changes in oxygen requirement. Although oxygen requirements and respiratory rates were lower in the short binasal prong group any important differences in other outcomes, such as requirement for endotracheal intubation, would be difficult to detect because of the small number of infants randomised. The greater relative maturity of these infants and the exclusion of any who had received antenatal steroids reduces the generalizability of these results.</P>
<P>
<B>3. Studies randomising preterm infants to different NCPAP systems using broad inclusion criteria</B>
</P>
<P>Any conclusions that may be drawn from the studies of <LINK REF="STD-Rego-2002" TYPE="STUDY">Rego 2002</LINK> and <LINK REF="STD-Buettiker-2004" TYPE="STUDY">Buettiker 2004</LINK> are limited by their broad inclusion of more mature preterm infants requiring respiratory support for many different clinical indications, although many of those included required treatment for respiratory distress syndrome or post-extubation support. The primary outcomes as specified in this review were not examined. In both studies, there was no significant difference between the NCPAP devices used for the outcome of air leak. <LINK REF="STD-Rego-2002" TYPE="STUDY">Rego 2002</LINK> showed that Argyle prongs were more likely to cause nasal hyperaemia when compared with Hudson prongs. <LINK REF="STD-Buettiker-2004" TYPE="STUDY">Buettiker 2004</LINK> showed no significant difference in the rates of nasal trauma between the NCPAP devices investigated. Both of these trials were limited in their capacity to show significant differences in the rates of nasal trauma because the more mature preterm infants enrolled in these studies required relatively short times on NCPAP.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-05-30 13:23:30 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-05-30 13:23:30 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>1. Preterm infants being extubated to NCPAP following a period of IPPV for RDS</B>
</P>
<P>Short binasal prong devices are more effective than single prongs in reducing the likelihood of the short-term adverse outcomes of re-intubation and respiratory failure. In a single study (available in abstract form only) the Infant Flow system appears more effective than Medicorp prongs. Although the comparison of the Infant Flow Driver with INCA prong NCPAP demonstrated a shorter hospital stay for the Infant Flow Driver treated group, there were no significant differences in the primary outcome or in other more important secondary outcomes. Consequently, the most effective short binasal prong device remains to be determined. It is unclear whether the superiority of the Infant Flow system demonstrated in these studies is attributable to its prongs or to its method of generating pressure.</P>
<P>
<B>2. Preterm infants initially treated with NCPAP soon after birth, either prophylactically or as treatment for RDS</B>
</P>
<P>The reduction in oxygen requirements and respiratory rate with short binasal prongs suggests they are more effective than single prong nasopharyngeal CPAP in the treatment of RDS. The short-term primary outcomes of this trial do not allow conclusions to be made on some medium-term (e.g. chronic lung disease at 36 weeks postmenstrual age) and long-term outcomes.</P>
<P>At present the only randomised trial directly comparing different pressure sources for NCPAP delivery (<LINK REF="STD-Colaizy-2004" TYPE="STUDY">Colaizy 2004</LINK>) is only available in abstract form and further data is required before its inclusion in this review. The choice of pressure source may then be based on cost-effectiveness and ease of use.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further research in preterm infants requiring NCPAP for respiratory support is required to focus on defining the optimal short binasal prong devices. In addition to assessing important longer-term outcomes such as mortality, chronic lung disease, time on respiratory support, length of hospital stay, gastrointestinal complications and neurodevelopment, attention should also be directed at determining which device is least traumatic to the infant nose, particularly in very low birth weight infants. Studies comparing nasal devices should ensure that the prescribed starting pressure at the nasal level is the same and that sufficient flow to meet inspiratory demands is applied in each treatment arm. Randomised studies comparing different techniques of pressure generation need to control for the resistance of the nasal prong in each group. Comparisons of pressure generation via the Infant Flow system, underwater bubble system and via ventilator would be of most interest.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank the authors Drs Sun and Davis for providing unpublished information. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Dr Peter Davis and Brenda Faber are authors of one of the trials included in this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>The authors De Paoli, Davis and Faber developed the protocol, performed the literature search, data collection and analysis. Professor Morley acted as a content expert throughout the writing of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Buettiker-2004" NAME="Buettiker 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buettiker V, Hug MI, Baenziger O, Meyer C, Frey B</AU>
<TI>Advantages and disadvantages of different nasal CPAP systems in newborns</TI>
<SO>Intensive Care Medicine</SO>
<YR>2004</YR>
<VL>30</VL>
<PG>926-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Davis-2001" NAME="Davis 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis P, Davies M, Faber B</AU>
<TI>A randomised controlled trial of two methods of delivering nasal continuous positive airway pressure after extubation to infants weighing less than 1000g: binasal (Hudson) versus single nasal prongs</TI>
<SO>Archives of Disease in Childhood Fetal Neonatal Ed</SO>
<YR>2000</YR>
<VL>85</VL>
<PG>F82-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazzella-2001" NAME="Mazzella 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mazzella M, Bellini C, Calevo MG, Campone F, Massocco D, Mezzano P, Zullino E, Scopesi F, Arioni C, Bonacci W, Serra G</AU>
<TI>A randomised control study comparing the Infant Flow Driver with nasal continuous positive airway pressure in preterm infants</TI>
<SO>Archives of Disease in Childhood Fetal Neonatal Ed</SO>
<YR>2001</YR>
<VL>85</VL>
<PG>F86-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rego-2002" NAME="Rego 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Abstract describes random allocation of 96 preterm infants to NCPAP either by Hudson prong or Argyle prong. Heterogeneous inclusion criteria (babies with apnoea, respiratory distress syndrome, pneumonia, transient tachypnoea of the newborn and those 'weaning from the ventilator' were randomised). Await full publication for further information.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rego MAC, Martinez FE</AU>
<TI>Comparison of two nasal prongs for application of continuous positive airway pressure in neonates</TI>
<SO>Pediatric Critical Care Medicine</SO>
<YR>2002</YR>
<VL>3</VL>
<PG>239-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roukema-1999a" NAME="Roukema 1999a" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roukema H, O'Brien K, Nesbitt K, Zaw W</AU>
<TI>A randomized controlled trial of Infant Flow continuous positive airway pressure (CPAP) versus nasopharyngeal CPAP in the extubation of babies &lt;=1250g (abstract)</TI>
<SO>Pediatric Research</SO>
<YR>1999</YR>
<VL>45</VL>
<PG>318A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stefanescu-2003" NAME="Stefanescu 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Abstract presents preliminary data on 148 infants randomised either to Infant Flow CPAP system or CPAP via INCA prongs with conventional ventilator. Total of 162 randomised in the study. The number of infants allocated to each group was not stated in the abstract. Awaiting full publication.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stefanescu BM, Murphy WP, Hansell BJ, Fuloria M, Morgan TM, Aschner JL</AU>
<TI>A randomized, controlled trial comparing two different continuous positive airway pressure systems for the successful extubation of extremely low birth weight infants</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>112</VL>
<PG>1031-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sun-1999" NAME="Sun 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun SC, Tien HC</AU>
<TI>Randomized controlled trial of two methods of nasal CPAP (NCPAP): Flow Driver vs conventional NCPAP (abstract)</TI>
<SO>Pediatric Research</SO>
<YR>1999</YR>
<VL>45</VL>
<PG>322A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahluwalia-1998" NAME="Ahluwalia 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Although randomised did not study the target population for the review (ie post-extubation or as primary treatment for respiratory distress). They examined any infant treated with NCPAP and supplemental oxygen.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahluwalia JS, White DK, Morley CJ</AU>
<TI>Infant Flow Driver or single prong nasal continuous positive airway pressure: short-term physiological effects</TI>
<SO>Acta Paediatrica</SO>
<YR>1998</YR>
<VL>87</VL>
<PG>325-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhandari-1996" NAME="Bhandari 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Retrospective evaluation, non randomized.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bhandari V, Rogerson S, Barfield C, Yu V, Rowe JC</AU>
<TI>Nasal versus naso-pharyngeal continuous positive airway pressure (CPAP) use in preterm neonates (abstract)</TI>
<SO>Pediatric Research</SO>
<YR>1996</YR>
<VL>39 (Suppl)</VL>
<PG>196A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campbell-2004" NAME="Campbell 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Campbell DM, Shah P, Shah V, Kelly E</AU>
<TI>High flow nasal cannula CPAP versus infant flow nasal CPAP in newly-extubated neonates &lt; 1250 g (abstract)</TI>
<SO>Pediatric Research</SO>
<YR>2004</YR>
<VL>56</VL>
<PG>472A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Courtney-2001" NAME="Courtney 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Although randomised did not study the target population for the review (ie post-extubation or as primary treatment for respiratory distress). They examined preterm infants treated with NCPAP for apnoea or mild respiratory distress.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Courtney SE, Pyon KH, Saslow JG, Arnold GK, Pandit PB, Habib RH</AU>
<TI>Lung recruitment and breathing pattern during variable versus continuous flow nasal continuous positive airway pressure in premature infants: an evaluation of three devices</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>107</VL>
<PG>304-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jonsson-1998" NAME="Jonsson 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Although randomised did not study the target population for the review (ie post-extubation or as primary treatment for respiratory distress). Babes were randomised on day 3 of life after NCPAP treatment in the first 3 days.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jonsson B, Repfennig L, Eriksson M, Lagercrantz H</AU>
<TI>The Scandanavian mode of respiratory therapy: a physiologic study of the Infant Flow nasal CPAP (abstract)</TI>
<SO>Pediatric Research</SO>
<YR>1998</YR>
<VL>43</VL>
<PG>178A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kavvadia-2000" NAME="Kavvadia 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Study of single prong versus Infant Flow NCPAP in the post-extubation period but without randomisation.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kavvadia V, Greenough A, Dimitriou G</AU>
<TI>Effect on lung function of continuous positive airway pressure administered either by Infant Flow Driver or a single nasal prong</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2000</YR>
<VL>159</VL>
<PG>289-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liptsen-2005" NAME="Liptsen 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liptsen E, Aghai ZH, Pyon KH, Saslow JG, Nakhla T, Long J, Steele AM, Habib RH, Courtney SE</AU>
<TI>Work of breathing during nasal continuous positive airway pressure in preterm infants: a comparison of bubble vs variable-flow devices</TI>
<SO>Journal of Perinatology</SO>
<YR>2005</YR>
<VL>25</VL>
<PG>453-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massaro-2005" NAME="Massaro 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Massaro AN, Abdel-Haq I, Aly H</AU>
<TI>Underwater seal "bubble CPAP" versus ventilator derived CPAP: does mode of delivery make a difference in clinical outcome? (abstract)</TI>
<SO>E-PAS [www.pas-meeting.org/]</SO>
<YR>2005</YR>
<VL>57</VL>
<PG>2054</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nair-2005" NAME="Nair 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nair G, Karna P</AU>
<TI>Comparison of the effects of Vapotherm and nasal CPAP in respiratory distress in preterm infants (abstract)</TI>
<SO>E-PAS [www.pas-meeting.org/]</SO>
<YR>2005</YR>
<VL>57</VL>
<PG>2054</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Narendran-2002" NAME="Narendran 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Narendran V, Donovan EF, Hoath SB, Warner BB, Steichen JJ, Jobe AH</AU>
<TI>Comparison between early bubble CPAP and conventional CPAP in reducing the incidence of chronic lung disease (abstract)</TI>
<SO>E-PAS [www.pas-meeting.org/]</SO>
<YR>2002</YR>
<VL>51</VL>
<PG>1960</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pandit-2001" NAME="Pandit 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Did not examine the population (studied infants with minimal lung disease) or a priori outcomes.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pandit PB, Courtney SE, Pyon KH, Saslow JG, Habib RH</AU>
<TI>Work of breathing during constant- and variable-flow nasal continuous positive airway pressure in preterm neonates</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>108</VL>
<PG>682-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pelligra-2006" NAME="Pelligra 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pelligra G, Abdellatif MA, Lee SK</AU>
<TI>Comparison of clinical outcomes between two modes of CPAP delivery: underwater "bubble" versus conventional ventilator-derived (abstract)</TI>
<SO>E-PAS [www.pas-meeting.org/]</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>475</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roukema-1999b" NAME="Roukema 1999b" YEAR="1999b">
<REFERENCE NOTES="&lt;p&gt;Non randomised evaluation of those 'unsuccessful' babies attempting extubation on second and subsequent attempts, using the alternative CPAP method to that used on the first attempt in the included study: Roukema H, et al, A randomized controlled trial of infant flow continuous positive airway pressure (CPAP) versus nasopharyngeal CPAP in the extubation of babies &amp;lt;=1250g (abstr), Pediatr Res, 1999;45:318A.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roukema H, O'Brien K, Nesbitt K, Zaw W</AU>
<TI>A crossover trial of Infant Flow continuous positive airway pressure versus nasopharyngeal CPAP in the extubation of babies &lt;= 1250 grams birthweight (abstract)</TI>
<SO>Pediatric Research</SO>
<YR>1999</YR>
<VL>45</VL>
<PG>317A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sreenan-2001" NAME="Sreenan 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sreenan C, Lemke RP, Hudson-Mason A, Osiovich H</AU>
<TI>High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>107</VL>
<PG>1081-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Telenko-1999" NAME="Telenko 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Although randomised did not study the target population for the review (ie post-extubation or as primary treatment for respiratory distress). Examined population of preterm infants with apnoea of prematurity. ? NCPAP device types&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Telenko T, Peliowski A, Hudson-Mason A</AU>
<TI>Continuous positive airway pressure (CPAP) in the treatment of apnea of prematurity: a comparison of two CPAP delivery systems (abstract)</TI>
<SO>Pediatric Research</SO>
<YR>1999</YR>
<VL>45</VL>
<PG>228A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trevisanuto-2005" NAME="Trevisanuto 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trevisanuto D, Grazzina N, Doglioni N, Ferrarese P, Marzari F, Zanardo V</AU>
<TI>A new device for administration of continuous positive airway pressure in preterm infants: comparison with a standard nasal CPAP continuous positive airway pressure system</TI>
<SO>Intensive Care Medicine</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>859-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yong-2005" NAME="Yong 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yong SC, Chen SJ, Boo NY</AU>
<TI>Incidence of nasal trauma associated with nasal prong versus nasal mask during continuous positive airway pressure treatment in very low birth weight infants: a randomised control study</TI>
<SO>Archives of Disease in Childhood Fetal Neonatal Ed</SO>
<YR>2005</YR>
<VL>90</VL>
<PG>F480-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Colaizy-2004" NAME="Colaizy 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Colaizy TT, McEvoy C, Crichton C, Freitag BC, Gilhooly J, Pillers DM, Smith SA, Wallen L</AU>
<TI>Bubble vs. conventional CPAP: a prospective, randomized, pilot study (abstract)</TI>
<SO>Pediatric Academic Societies [www.pas-meeting.org/]</SO>
<YR>2004</YR>
<VL>55</VL>
<PG>2646</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Ackerman-1974" NAME="Ackerman 1974" TYPE="JOURNAL_ARTICLE">
<AU>Ackerman BD, Stein MP, Sommer JS, Schumacher M</AU>
<TI>Continuous positive airway pressure applied by means of a tight-fitting mask</TI>
<SO>Journal of Pediatrics</SO>
<YR>1974</YR>
<VL>85</VL>
<PG>408-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Agostino-1973" NAME="Agostino 1973" TYPE="JOURNAL_ARTICLE">
<AU>Agostino R, Orzalesi M, Nodari S, Mendicini M, Conca L, Savignoni PG, Picece-Bucci S, Calliumi G, Bucci G</AU>
<TI>Continuous positive airway pressure by nasal cannula in the respiratory distress syndrome of the newborn</TI>
<SO>Pediatric Research</SO>
<YR>1973</YR>
<VL>7</VL>
<PG>50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ahlstrom-1973" NAME="Ahlstrom 1973" TYPE="JOURNAL_ARTICLE">
<AU>Ahlstrom H, Jonson B, Svenningsen NW</AU>
<TI>Continuous positive airway pressure with a face chamber in early treatment of idiopathic respiratory distress syndrome</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1973</YR>
<VL>62</VL>
<PG>433-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Annibale-1994" NAME="Annibale 1994" TYPE="JOURNAL_ARTICLE">
<AU>Annibale DJ, Hulsey TC, Engstrom PC, Wallin LA, Ohning BL</AU>
<TI>Randomized, controlled trial of nasopharyngeal continuous positive airway pressure in the extubation of very low birth weight infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>1994</YR>
<VL>124</VL>
<PG>455-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barrie-1972" NAME="Barrie 1972" TYPE="JOURNAL_ARTICLE">
<AU>Barrie H</AU>
<TI>Simple method of applying continuous positive airway pressure in respiratory-distress syndrome</TI>
<SO>Lancet</SO>
<YR>1972</YR>
<VL>1</VL>
<PG>776-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benveniste-1976" NAME="Benveniste 1976" TYPE="JOURNAL_ARTICLE">
<AU>Benveniste D, Berg O, Pedersen JE</AU>
<TI>A technique for delivery of continuous positive airway pressure to the neonate</TI>
<SO>Journal of Pediatrics</SO>
<YR>1976</YR>
<VL>88</VL>
<PG>1015-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boros-1976" NAME="Boros 1976" TYPE="JOURNAL_ARTICLE">
<AU>Boros SJ, Reynolds JW</AU>
<TI>Prolonged apnea of prematurity: Treatment with continuous distending airway pressure delivered by nasopharyngeal tube</TI>
<SO>Clinical Pediatrics</SO>
<YR>1976</YR>
<VL>15</VL>
<PG>123-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caliumi_x002d_Pell.-1974" NAME="Caliumi-Pell. 1974" TYPE="JOURNAL_ARTICLE">
<AU>Caliumi-Pellegrini G, Agostino R, Orzalesi M, Nodari S, Marzetti G, Savignoni PG, Bucci G</AU>
<TI>Twin nasal cannula for administration of continuous positive airway pressure to newborn infants</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1974</YR>
<VL>49</VL>
<PG>228-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chernick-1973" NAME="Chernick 1973" TYPE="JOURNAL_ARTICLE">
<AU>Chernick V</AU>
<TI>Continuous distending pressure in hyaline membrane disease: of devices, disadvantages, and a daring study</TI>
<SO>Pediatrics</SO>
<YR>1973</YR>
<VL>52</VL>
<PG>114-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cox-1974" NAME="Cox 1974" TYPE="JOURNAL_ARTICLE">
<AU>Cox JMR, Boehm JJ, Millare EA</AU>
<TI>Individual nasal masks and intranasal tubes: A non-invasive neonatal technique for the delivery of continuous positive airway pressure (CPAP)</TI>
<SO>Anaesthesia</SO>
<YR>1974</YR>
<VL>29</VL>
<PG>597-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-2000" NAME="Davis 2000" TYPE="COCHRANE_REVIEW">
<AU>Davis PG, Henderson-Smart DJ</AU>
<TI>Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Paoli-2002" NAME="De Paoli 2002" TYPE="JOURNAL_ARTICLE">
<AU>De Paoli AG, Morley CJ, Davis PG, Lau R, Hingeley E</AU>
<TI>In vitro comparison of nasal continuous positive airway pressure devices for neonates</TI>
<SO>Archives of Disease in Childhood Fetal Neonatal Ed</SO>
<YR>2002</YR>
<VL>86</VL>
<PG>F42-F45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Field-1985" NAME="Field 1985" TYPE="JOURNAL_ARTICLE">
<AU>Field D, Vyas H, Milner AD, Hopkin IE</AU>
<TI>Continuous positive airway pressure via a single nasal catheter in preterm infants</TI>
<SO>Early Human Development</SO>
<YR>1985</YR>
<VL>11</VL>
<PG>275-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaon-1999" NAME="Gaon 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gaon P, Lee S, Hannan S, Ingram D, Milner AD</AU>
<TI>Assessment of effect of nasal continuous positive pressure on laryngeal opening using fibre optic laryngoscopy</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1999</YR>
<VL>80</VL>
<PG>F230-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldman-1979" NAME="Goldman 1979" TYPE="JOURNAL_ARTICLE">
<AU>Goldman SL, Brady JP, Dumpit FM</AU>
<TI>Increased work of breathing associated with nasal prongs</TI>
<SO>Pediatrics</SO>
<YR>1979</YR>
<VL>64</VL>
<PG>160-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gregory-1971" NAME="Gregory 1971" TYPE="JOURNAL_ARTICLE">
<AU>Gregory GA, Kitterman JA, Phibbs RH, Tooley WH, Hamilton WK</AU>
<TI>Treatment of the idiopathic respiratory-distress syndrome with continuous positive airway pressure</TI>
<SO>New England Journal of Medicine</SO>
<YR>1971</YR>
<VL>284</VL>
<PG>1333-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harris-1972" NAME="Harris 1972" TYPE="JOURNAL_ARTICLE">
<AU>Harris TR</AU>
<TI>Continuous positive airway pressure applied by face mask (abstract)</TI>
<SO>Pediatric Research</SO>
<YR>1972</YR>
<VL>6</VL>
<PG>410</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harris-1976" NAME="Harris 1976" TYPE="JOURNAL_ARTICLE">
<AU>Harris H, Wilson S, Brans Y,Wirtschafter D, Cassady G</AU>
<TI>Nasal continuous positive airway pressure. Improvement in arterial oxygenation in hyaline membrane disease</TI>
<SO>Biology of the Neonate</SO>
<YR>1976</YR>
<VL>29</VL>
<PG>231-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-1991" NAME="Higgins 1991" TYPE="JOURNAL_ARTICLE">
<AU>Higgins RD, Richter SE, Davis JM</AU>
<TI>Nasal continuous positive airway pressure facilitates extubation of very low birth weight neonates</TI>
<SO>Pediatrics</SO>
<YR>1991</YR>
<VL>88</VL>
<PG>999-1003</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kamper-1990" NAME="Kamper 1990" TYPE="JOURNAL_ARTICLE">
<AU>Kamper J, Ringsted C</AU>
<TI>Early treatment of idiopathic respiratory distress syndrome using binasal continuous positive airway pressure</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1990</YR>
<VL>79</VL>
<PG>581-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kattwinkel-1973" NAME="Kattwinkel 1973" TYPE="JOURNAL_ARTICLE">
<AU>Kattwinkel J, Fleming D, Cha CC, Fanaroff AA, Klaus MH</AU>
<TI>A device for administration of continuous positive airway pressure by the nasal route</TI>
<SO>Pediatrics</SO>
<YR>1973</YR>
<VL>52</VL>
<PG>131-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klausner-1996" NAME="Klausner 1996" TYPE="UNPUBLISHED">
<AU>Klausner JF, Lee AY, Hutchison AA</AU>
<TI>Decreased imposed work with a new nasal continuous positive airway pressure device</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1996</YR>
<VL>22</VL>
<PG>188-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krouskop-1975" NAME="Krouskop 1975" TYPE="JOURNAL_ARTICLE">
<AU>Krouskop RW, Brown EG, Sweet AY</AU>
<TI>The early use of continuous positive airway pressure in the treatment of idiopathic respiratory distress syndrome</TI>
<SO>Journal of Pediatrics</SO>
<YR>1975</YR>
<VL>87</VL>
<PG>263-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-1998" NAME="Lee 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lee KS, Dunn MS, Fenwick M, Shennan AT</AU>
<TI>A comparison of underwater bubble continuous positive airway pressure with ventilator-derived continuous positive airway pressure in premature neonates ready for extubation</TI>
<SO>Biology of the Neonate</SO>
<YR>1998</YR>
<VL>73</VL>
<PG>69-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Locke-1991" NAME="Locke 1991" TYPE="JOURNAL_ARTICLE">
<AU>Locke R, Greenspan JS, Shaffer TH, Rubenstein SD, Wolfson MR</AU>
<TI>Effect of nasal CPAP on thoracoabdominal motion in neonates with respiratory insufficiency</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1991</YR>
<VL>11</VL>
<PG>259-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Locke-1993" NAME="Locke 1993" TYPE="JOURNAL_ARTICLE">
<AU>Locke RG, Wolfson MR, Shaffer TH, Rubenstein SD, Greenspan JS</AU>
<TI>Inadvertent administration of positive end-distending pressure during nasal cannula flow</TI>
<SO>Pediatrics</SO>
<YR>1993</YR>
<VL>91</VL>
<PG>135-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loftus-1994" NAME="Loftus 1994" TYPE="JOURNAL_ARTICLE">
<AU>Loftus BC, Ahn J, Haddad J</AU>
<TI>Neonatal nasal deformities secondary to nasal continuous positive airway pressure</TI>
<SO>Laryngoscope</SO>
<YR>1994</YR>
<VL>104</VL>
<PG>1019-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martin-1977" NAME="Martin 1977" TYPE="JOURNAL_ARTICLE">
<AU>Martin RJ, Nearman HS, Katona PG, Klaus MH</AU>
<TI>The effect of a low continuous positive airway pressure on the reflex control of respiration in the preterm infant</TI>
<SO>Journal of Pediatrics</SO>
<YR>1977</YR>
<VL>90</VL>
<PG>976-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-1985" NAME="Miller 1985" TYPE="JOURNAL_ARTICLE">
<AU>Miller MJ, Carlo WA, Martin RJ</AU>
<TI>Continuous positive airway pressure selectively reduces obstructive apnea in preterm infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>1985</YR>
<VL>106</VL>
<PG>91-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-1990" NAME="Miller 1990" TYPE="JOURNAL_ARTICLE">
<AU>Miller MJ, DiFiore JM, Strohl KP, Martin RJ</AU>
<TI>Effects of nasal CPAP on supraglottic and total pulmonary resistance in preterm infants</TI>
<SO>Journal of Applied Physiology</SO>
<YR>1990</YR>
<VL>68</VL>
<PG>141-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moa-1988" NAME="Moa 1988" TYPE="JOURNAL_ARTICLE">
<AU>Moa G, Nilsson K, Zetterstrom H, Jonsson LO</AU>
<TI>A new device for administration of nasal continuous positive airway pressure in the newborn: An experimental study</TI>
<SO>Critical Care Medicine</SO>
<YR>1988</YR>
<VL>16</VL>
<PG>1238-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Novogroder-1973" NAME="Novogroder 1973" TYPE="JOURNAL_ARTICLE">
<AU>Novogroder M, MacKuanying N, Eidelman AI, Gartner LM</AU>
<TI>A simple and efficient method of delivering continuous positive airway pressure</TI>
<SO>Journal of Pediatrics</SO>
<YR>1973</YR>
<VL>82</VL>
<PG>1059-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pandit-1999" NAME="Pandit 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pandit PB, Pyon KH, Courtney SE, Habib RH</AU>
<TI>Inspiratory work of breathing with a demand flow vs constant flow nasal continuous positive airway pressure device in preterm neonates (abstr)</TI>
<SO>Pediatric Research</SO>
<YR>1999</YR>
<VL>45</VL>
<PG>314A: 1850</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pape-1976" NAME="Pape 1976" TYPE="JOURNAL_ARTICLE">
<AU>Pape KE, Armstrong DL, Fitzhardinge PM</AU>
<TI>Central nervous system pathology associated with mask ventilation in the very low birth weight infant: a new etiology for intracerebellar hemorrhages</TI>
<SO>Pediatrics</SO>
<YR>1976</YR>
<VL>58</VL>
<PG>473-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pedersen-1994" NAME="Pedersen 1994" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen JE, Nielsen K</AU>
<TI>Oropharyngeal and esophageal pressures during mono- and binasal CPAP in neonates</TI>
<SO>Acta Paediatrica</SO>
<YR>1994</YR>
<VL>83</VL>
<PG>143-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rhodes-1973" NAME="Rhodes 1973" TYPE="JOURNAL_ARTICLE">
<AU>Rhodes PG, Hall RT</AU>
<TI>Continuous positive airway pressure delivered by face mask in infants with the idiopathic respiratory distress syndrome: a controlled study</TI>
<SO>Pediatrics</SO>
<YR>1973</YR>
<VL>52</VL>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richardson-1978" NAME="Richardson 1978" TYPE="JOURNAL_ARTICLE">
<AU>Richardson CP, Jung AL</AU>
<TI>Effects of continuous positive airway pressure on pulmonary function and blood gases of infants with respiratory distress syndrome</TI>
<SO>Pediatric Research</SO>
<YR>1978</YR>
<VL>12</VL>
<PG>771-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robertson-1996" NAME="Robertson 1996" TYPE="JOURNAL_ARTICLE">
<AU>Robertson NJ, McCarthy LS, Hamilton PA, Moss ALH</AU>
<TI>Nasal deformities resulting from Flow Driver continuous positive airway pressure</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1996</YR>
<VL>75</VL>
<PG>F209-F212</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-So-1992" NAME="So 1992" TYPE="JOURNAL_ARTICLE">
<AU>So BH, Shibuya K, Tamura M, Watanabe H, Kamoshita S</AU>
<TI>Clinical experience in using a new type of nasal prong for administration of N-CPAP</TI>
<SO>Acta Paediatrica Japonica</SO>
<YR>1992</YR>
<VL>34</VL>
<PG>328-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Subramaniam-2000" NAME="Subramaniam 2000" TYPE="COCHRANE_REVIEW">
<AU>Subramaniam P, Henderson-Smart DJ, Davis PG</AU>
<TI>Prophylactic nasal continuous positive airways pressure for preventing morbidity in very preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vert-1973" NAME="Vert 1973" TYPE="JOURNAL_ARTICLE">
<AU>Vert P, Andre M, Sibout M</AU>
<TI>Continuous positive airway pressure and hydrocephalus (letter)</TI>
<SO>Lancet</SO>
<YR>1973</YR>
<VL>2</VL>
<PG>319</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wung-1975" NAME="Wung 1975" TYPE="JOURNAL_ARTICLE">
<AU>Wung JT, Driscoll JM, Epstein RA, Hyman AI</AU>
<TI>A new device for CPAP by nasal route</TI>
<SO>Critical Care Medicine</SO>
<YR>1975</YR>
<VL>3</VL>
<PG>76-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yu-1977" NAME="Yu 1977" TYPE="JOURNAL_ARTICLE">
<AU>Yu VYH, Rolfe P</AU>
<TI>Effect of continuous positive airway pressure breathing on cardiorespiratory function in infants with respiratory distress syndrome</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1977</YR>
<VL>66</VL>
<PG>59-64</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-De-Paoli-2002a" NAME="De Paoli 2002a" TYPE="COCHRANE_REVIEW">
<AU>De Paoli AG, Davis PG, Faber B, Morley CJ</AU>
<TI>Devices and pressure sources for administration of nasal continuous positive airway pressure (NCPAP) in preterm neonates</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Buettiker-2004">
<CHAR_METHODS>
<P>Method of randomisation: not specified. <BR/>Intervention blinded: no<BR/>Follow-up complete.<BR/>Blinding of outcome assessment not specified.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Neonates with respiratory distress of birthweight 1250g or greater and less than or equal to 28 days of life.<BR/>Total number randomised: 40<BR/>(1250-2500g: 20, &gt;2500g: 20) <BR/>Inclusion criteria for both non-intubated infants and those after extubation:<BR/>1. Clinical signs of respiratory distress and,<BR/>2. FiO2 &gt;0.4 and PaCO2 &gt;52mmHg (or capillary PCO2&gt; 56mmHg)<BR/>Exclusions:<BR/>1. Congenital heart disease<BR/>2. Necrotising enterocolitis<BR/>3. Upper airway anomalies</P>
<P>One infant with neuromuscular disease and one with Jeune syndrome included.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Naso- pharyngeal CPAP via a single tube attached to a conventional ventilator (n = 16)<BR/>2. NCPAP via Hudson prongs attached to a conventional ventilator (n = 12)<BR/>3. NCPAP via IFD</P>
<P>CPAP pressure routinely used: 3-5 cmH2O.<BR/>Flow not specified.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Nasal trauma<BR/>2. Air leak syndromes<BR/>3. CPAP tube blockage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Davis-2001">
<CHAR_METHODS>
<P>Blinding of randomisation: yes; sealed, opaque, sequentially numbered envelopes<BR/>Intervention blinded: no<BR/>Complete follow-up: yes<BR/>Outcome assessment blinded: no<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Ventilated preterm infants prior to extubation <BR/>Total randomised: 87<BR/>1. BW &lt;1000g<BR/>2. Intubated<BR/>3. Ventilator rate &lt;= 20/min<BR/>4. FiO2 &lt;= 0.5<BR/>5. Clinician agrees to extubation<BR/>6. Loaded with aminophylline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: NCPAP via Hudson prongs attached to conventional ventilator (n = 41) <BR/>Control: NCPAP via single prong (Portex tube size 2.5 or 3.0) inserted to 2.5 cm, attached to conventional ventilator (n = 46)</P>
<P>Both groups had set flows of 6 L/min and initial pressures of 7 cmH2O</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Respiratory failure defined as 1. frequent apnoea requiring stimulation or episode requiring bag and mask ventilation, 2. FiO2 15% above extubation level, 3. pH&lt; 7.25 with PCO2 &gt; 50 mmHg<BR/>Other outcomes included:<BR/>Need for additional respiratory support within the 7 days following removal of the endotracheal tube death, BPD, IVH, PVL, ROP sepsis, feeding intolerance, weight gain, days of respiratory support, days in level III hospital<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Planned sample size of 130 however trial was stopped after 87 on the advice of an external monitoring committee, based on a prespecified stopping rule.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mazzella-2001">
<CHAR_METHODS>
<P>Blinding of randomisation: yes; sealed, numbered envelopes<BR/>Intervention blinded: no<BR/>Complete follow-up: yes<BR/>Outcome assessment blinded: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Non-intubated preterm infants with early respiratory distress <BR/>Total randomised: 36<BR/>1. GA &lt; 36 weeks<BR/>2. age &lt; 12 hours<BR/>3. PCO2 &lt; 65 mmHg<BR/>4. FiO2 &gt; 30%<BR/>5. CXR showing poor lung expansion<BR/>Exclusion:<BR/>1. Major congenital malformation<BR/>2. Neuromuscular diseases<BR/>3. Severe birth asphyxia<BR/>4. Overwhelming infection<BR/>5. Severe apnoea<BR/>6. PDA<BR/>7. Intubation at delivery<BR/>8. Antenatal steroids<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: NCPAP via IFD (n = 18)<BR/>Control: Single nasopharyngeal tube, pressure generated by underwater seal (n = 18)</P>
<P>Both groups' starting pressure: 4 cmH2O (could be increased to a maximum of 6 cmH2O)<BR/>Flow in IFD group 6-8L/min<BR/>Flow in nasopharyngeal group 4-7 L/min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: change in O2 requirement and / or respiratory rate<BR/>Secondary: included success rate of weaning from NCPAP, death, IVH, oxygen dependency at day 28, pneumothorax, nasal trauma<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rego-2002">
<CHAR_METHODS>
<P>Randomisation by drawing lots.<BR/>Intervention blinded: no<BR/>Follow-up: incomplete as 3 infants were excluded from analysis for complications as their time on NCPAP was less than 2 hours.<BR/>Blinding of outcome assessment not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Neonates (total randomised = 99) requiring NCPAP for primary respiratory support (n=71) or for post-extubation support (n=28) of weight &lt;= 2500g.<BR/>Primary respiratory support inclusion criteria:<BR/>1. Silverman-Anderson retraction score of &gt;3 or,<BR/>2. Increasing FiO2 to maintain PaO2&gt;50mmHg or,<BR/>3. PaCO2 &gt;60mmHg and pH&lt;7.20 or,<BR/>4. Three or more apnoeic episodes during a 4 hour period or apnoeic episodes requiring vigorous stimulation, increased FiO2 or mask ventilation.<BR/>Primary respiratory support diagnoses:<BR/>1. Respiratory distress syndrome [n=34]<BR/>2. Transient tachypnoea of the newborn [n=21],<BR/>3. Apnoea of prematurity (n=12)<BR/>4. Pneumonia (n=4)<BR/>Post-extubation: Ventilated infants placed on NCPAP when peak inspiratory pressure &lt;16cmH2O and respiratory rate &lt;20/minute <BR/>Exclusions: major cardiac disease or facial malformations.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Hudson prong NCPAP delivered by conventional ventilator with pressure fixed at 5cmH2O and flow from 5 to 10 L/minute.<BR/>2. Argyle prong CPAP delivered by conventional ventilator with pressure fixed at 5cmH2O and flow from 5 to 10 L/minute.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. CPAP 'success' defined as avoiding intubation and weaning off CPAP without requiring recommencement of CPAP in the 72 hours following cessation. Discontinuation of CPAP was at the discretion of attending staff.<BR/>2. Respiratory rate<BR/>3. Heart rate<BR/>3. Silverman-Anderson retraction score<BR/>4. pH and pCO2 before, and 2, 24, and 48 hours after commencement of NCPAP (arterial and capillary specimens).<BR/>5. Hours on NCPAP.<BR/>6. Frequency of abdominal distension.<BR/>7. Frequency per 24 hours of requirement for device removal from the nostrils<BR/>8. Nasal trauma (hyperaemia, bleeding, septum necrosis)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Heterogeneous diagnoses in primary respiratory support group (including respiratory distress and apnoea of prematurity).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Roukema-1999a">
<CHAR_METHODS>
<P>Blinding of randomisation: unclear<BR/>Intervention blinded: no<BR/>Complete follow-up: yes<BR/>Outcome assessment blinded: no<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Ventilated preterm infants prior to extubation <BR/>Total randomised: 93<BR/>1. BW &lt; 1251g<BR/>2. Intubated<BR/>3. Decision made to extubate<BR/>Exclusion:<BR/>1. Signs of upper airway obstruction<BR/>2. Airway anomalies</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: NCPAP via IFD (n = 48)<BR/>Control: 'Conventional' nasopharyngeal CPAP.<BR/>Pressure and flow not stated (n = 45)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: remaining extubated for 7 days<BR/>Indications for intubation or respiratory failure criteria not stated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Randomisation was blocked into three weight groups (250g increments).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stefanescu-2003">
<CHAR_METHODS>
<P>Blinding of randomisation: yes; table of random numbers and sealed opaque envelopes. Randomisation stratified into three birth weight blocks: &lt;= 600g, 601 to 800g, and 801 to 1000g.<BR/>Intervention blinded: no<BR/>Complete follow-up: yes.<BR/>Outcome assessment blinding: limited to blinding of radiologists (assessing cranial ultrasounds) to treatment allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Ventilated preterm infants of birth weight &lt;= 1000g prior to first extubation attempt.<BR/>Suggested extubation criteria:<BR/>1. Mean airway pressure &lt;= 5 cmH2O on conventional ventilation or &lt;= 7cmH2O on high frequency ventilation<BR/>2. FiO2 &lt;= 0.3<BR/>3. pH &gt;= 7.25<BR/>4. pCO2 &lt;= 65 mmHg <BR/>Total randomised: 162<BR/>Exclusions:<BR/>1. Major chromosomal anomalies.<BR/>2. Known airway anomalies.<BR/>3. Neuromuscular disorders<BR/>4. Other major congenital malformations<BR/>5. Participation in a concurrent randomised controlled trial.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Infant Flow NCPAP system.<BR/>Control: INCA binasal prongs with pressure generation via conventional ventilator.<BR/>Commencing NCPAP pressure for both treatment arms: 4-6 cmH2O.<BR/>Flow not specified for either treatment arm.<BR/>Minimum of 24 hours of NCPAP treatment for both arms.<BR/>Protocol specified administration of methylxanthine therapy to all infants prior to extubation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: reduction in the percentage of infants failing extubation defined as the requirement for re-intubation within 168 hours (7 days) of extubation.<BR/>Criteria for re-intubation:<BR/>1. SaO2 &lt; 88% in FiO2 &gt;= 0.5.<BR/>2. PaCO2 &gt;= 65 mmHg with arterial pH &lt; 7.25<BR/>3. CPAP requirement &gt; 8 cmH2O.<BR/>4. Recurrent significant apnoea or bradycardia.<BR/>Secondary outcomes:<BR/>1. Death<BR/>2. Survival without BPD<BR/>3. Number of days on CPAP<BR/>4. Days on supplemental oxygen<BR/>5. Length of hospitalisation<BR/>6. Necrotising enterocolitis<BR/>7. Patent ductus arteriosus<BR/>8. Sepsis<BR/>9. Intraventricular haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sun-1999">
<CHAR_METHODS>
<P>Blinding of randomisation: yes, sealed envelopes, mixed and picked at random<BR/>Intervention blinded: no<BR/>Complete follow-up: yes<BR/>Outcome assessment blinded: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Ventilated preterm infants prior to extubation <BR/>Total randomised: 100<BR/>1. GA &lt; 31 weeks<BR/>2. BW &lt; 1251g<BR/>3. Respiratory distress syndrome<BR/>4. Intubated<BR/>5. MAP &lt; 7 cmH2O<BR/>6. FiO2 &lt;= 0.30<BR/>7. Daily caloric intake: <BR/>&gt;= 50 kcal/kg/day for &gt;=12 hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: NCPAP via IFD<BR/>Control: 'Conventional' NCPAP system (Medicorp nasal prongs: short binasal)<BR/>Commencing pressures: <BR/>IFD: flow adjusted to attain pressure of <BR/>5 cmH2O (n = 50)<BR/>Conventional: expiratory valve adjusted to attain pressure of 5 cmH2O (n = 50)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Failure of extubation defined as: 1. NCPAP required <BR/>&gt; 8 cmH2O, 2. FiO2 &gt; 0.60 to maintain SaO2 at 88-95%, 3. PCO2 &gt; 65 mmHg with pH &lt; 7.25, 4. recurrent apnoeas / bradycardias</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BPD: bronchopulmonary dysplasia<BR/>PVL: periventricular leucomalacia<BR/>ROP: retinopathy of prematurity<BR/>IVH: intraventricular haemorrhage<BR/>GA: gestational age<BR/>PDA: patent ductus arteriosus<BR/>IFD: Infant flow driver<BR/>MAP: mean airway pressure</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ahluwalia-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>This randomised study did not examine the target preterm population for this review (ie immediately post-extubation or needing primary treatment for respiratory distress syndrome). Any infant treated with NCPAP and supplemental oxygen was eligible.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bhandari-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>This comparison of nasal versus naso-pharyngeal CPAP was non randomized and retrospective.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Campbell-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compared Infant Flow CPAP with high-flow nasal cannulae. High-flow nasal cannulae is not a CPAP system that has an intrinsic pressure monitoring or pressure relief/blow-off system and does not meet the inclusion criteria for this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Courtney-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Although randomising infants to different NCPAP devices this study did not examine the target population for the review. They examined preterm infants treated with NCPAP for apnoea or mild respiratory distress.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jonsson-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Although randomised this study did not examine the target population for this review. Infants were randomised on day 3 of life after prior NCPAP treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kavvadia-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study was non-randomised. Single prong and Infant Flow NCPAP were compared in the post-extubation period.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liptsen-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compared bubble NCPAP with variable-flow NCPAP in preterm infants, however the outcome measures of work of breathing and breathing asynchrony did not meet the inclusion criteria for this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Massaro-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study was a non-randomized and retrospective comparison of bubble (underwater seal) CPAP and ventilator-derived CPAP and hence did not meet the inclusion criteria for this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nair-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compared the Vapotherm system (high flow nasal cannula system) with bubble nasal CPAP (prong type not specified) in preterm infants. Vapotherm (high-flow nasal cannula system) is not a NCPAP system that monitors pressure or has a pressure relief/blow-off system and hence was not included in this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Narendran-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study in extremely low birth weight infants used historical controls to compare bubble nasal CPAP with conventional CPAP (specific CPAP type not specified) and hence did not meet the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pandit-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study did not examine the target population for this review (infants with minimal lung disease were studied) or a priori outcomes applicable to the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pelligra-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study of CPAP in preterm infants used historical controls to compare bubble CPAP with conventional, ventilator-derived nasopharyngeal CPAP and hence did not meet inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roukema-1999b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised evaluation of those 'unsuccessful' infants attempting extubation on second and subsequent attempts, using the alternative CPAP method to that used on the first attempt in the included study: Roukema H, et al, A randomized controlled trial of infant flow continuous positive airway pressure (CPAP) versus nasopharyngeal CPAP in the extubation of babies &lt;=1250g (abstr), Pediatr Res, 1999;45:318A.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sreenan-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study examined infants with apnoea of prematurity and hence is not the target population for this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Telenko-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Although randomised did not study the target population for this review. Examined a population of preterm infants with apnoea of prematurity only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Trevisanuto-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compared Infant Flow nasal CPAP with CPAP delivered via a polycarbonate helmet. Helmet CPAP does not meet the a priori inclusion criteria of nasal interfaces for CPAP delivery.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yong-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study randomized very low birth weight infants to either nasal mask or via nasal masks are not currently in our inclusion criteria. to include this trial we would have to include this as a post-hoc comparison of interfaces. No outcomes assessed other than nasal trauma.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Colaizy-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Buettiker-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Davis-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Mazzella-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rego-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Roukema-1999a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Stefanescu-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sun-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Short binasal prong vs single nasal prong CPAP to prevent extubation failure</NAME>
<DICH_OUTCOME CHI2="0.20671616277809648" CI_END="0.7393863168652095" CI_START="0.303500013725051" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4737127371273713" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.13112859077254221" LOG_CI_START="-0.5178412849488101" LOG_EFFECT_SIZE="-0.3244849378606761" METHOD="MH" NO="1" P_CHI2="0.6493535202665226" P_Q="0.0" P_Z="0.0010048904430439887" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="92" WEIGHT="200.0" Z="3.2891539445703146">
<NAME>Extubation failure</NAME>
<GROUP_LABEL_1>Short binasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Single nasal prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single nasal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0408322293860992" CI_START="0.2713595030254182" DF="0.0" EFFECT_SIZE="0.5314505776636713" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.017380731697098657" LOG_CI_START="-0.5664549648004298" LOG_EFFECT_SIZE="-0.27453711655166557" NO="1" P_CHI2="1.0" P_Z="0.06528987458982005" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="1.8432681115208844">
<NAME>Endotracheal intubation within 7 days post-extubation</NAME>
<DICH_DATA CI_END="1.0408322293860992" CI_START="0.2713595030254182" EFFECT_SIZE="0.5314505776636713" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" LOG_CI_END="0.017380731697098657" LOG_CI_START="-0.5664549648004298" LOG_EFFECT_SIZE="-0.27453711655166557" ORDER="1" O_E="0.0" SE="0.34294797815595573" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.1176133157212579" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7827958220323943" CI_START="0.2378771655202614" DF="0.0" EFFECT_SIZE="0.43151969981238275" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.10635150094086174" LOG_CI_START="-0.623647245077097" LOG_EFFECT_SIZE="-0.3649993730089794" NO="2" P_CHI2="1.0" P_Z="0.0056771675996245986" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="2.7658670444769657">
<NAME>Respiratory failure within 7 days post-extubation</NAME>
<DICH_DATA CI_END="0.7827958220323943" CI_START="0.23787716552026134" EFFECT_SIZE="0.43151969981238275" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" LOG_CI_END="-0.10635150094086174" LOG_CI_START="-0.6236472450770971" LOG_EFFECT_SIZE="-0.3649993730089794" ORDER="2" O_E="0.0" SE="0.3038620807608558" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.09233216412431684" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Short binasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Single nasal prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single nasal</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.578327367462553" CI_START="0.29569282861349244" EFFECT_SIZE="1.6829268292682926" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9812896762493858" LOG_CI_START="-0.5291592082143461" LOG_EFFECT_SIZE="0.2260652340175198" ORDER="3" O_E="0.0" SE="0.8872451515765593" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.7872039589961116" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05551700248664902" CI_END="1.0550794430462977" CI_START="0.6492742003644916" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8276689324270291" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.0232851614135072" LOG_CI_START="-0.1875718539606768" LOG_EFFECT_SIZE="-0.08214334627358481" METHOD="MH" NO="3" P_CHI2="0.8137271953004357" P_Q="0.0" P_Z="0.1267405659201516" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="92" WEIGHT="200.0" Z="1.5270822265991368">
<NAME>Chronic lung disease</NAME>
<GROUP_LABEL_1>Short binasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Single nasal prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single nasal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.967061114426712E-31" CI_END="1.1527731028984272" CI_START="0.626695033214888" DF="0.0" EFFECT_SIZE="0.8499630450849962" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="33" I2="100.0" ID="CMP-001.03.01" LOG_CI_END="0.06174383473942711" LOG_CI_START="-0.2029437472274498" LOG_EFFECT_SIZE="-0.07059995624401133" NO="1" P_CHI2="0.0" P_Z="0.2957642492563691" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="1.045559980714789">
<NAME>Supplemental oxygen at day 28 of life</NAME>
<DICH_DATA CI_END="1.1527731028984274" CI_START="0.6266950332148881" EFFECT_SIZE="0.8499630450849963" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="33" LOG_CI_END="0.06174383473942719" LOG_CI_START="-0.20294374722744973" LOG_EFFECT_SIZE="-0.07059995624401127" ORDER="4" O_E="0.0" SE="0.15547879587200525" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.02417365596580868" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1835882203339612" CI_START="0.5426143118034259" DF="0.0" EFFECT_SIZE="0.8013937282229965" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="28" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.07320063419270408" LOG_CI_START="-0.26550875562550297" LOG_EFFECT_SIZE="-0.09615406071639947" NO="2" P_CHI2="1.0" P_Z="0.26579285298210686" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="1.1128034925312846">
<NAME>Supplemental oxygen at corrected gestational age of 36 weeks</NAME>
<DICH_DATA CI_END="1.1835882203339612" CI_START="0.5426143118034259" EFFECT_SIZE="0.8013937282229965" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="28" LOG_CI_END="0.07320063419270408" LOG_CI_START="-0.26550875562550297" LOG_EFFECT_SIZE="-0.09615406071639947" ORDER="5" O_E="0.0" SE="0.19895957221773494" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.03958491137706408" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.189925709143573" CI_END="1.3160120577447565" CI_START="0.8653245995291248" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0671352336248114" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.11925986844816622" LOG_CI_START="-0.06282094994508526" LOG_EFFECT_SIZE="0.028219459251540496" METHOD="MH" NO="4" P_CHI2="0.7846595340390234" P_Q="0.0" P_Z="0.5435040233619546" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="283" TOTAL_2="321" WEIGHT="700.0" Z="0.6075227943754118">
<NAME>Non-pulmonary outcomes</NAME>
<GROUP_LABEL_1>Short binasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Single nasal prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single nasal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.578327367462556" CI_START="0.2956928286134924" DF="0.0" EFFECT_SIZE="1.6829268292682926" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.9812896762493859" LOG_CI_START="-0.5291592082143463" LOG_EFFECT_SIZE="0.2260652340175198" NO="1" P_CHI2="1.0" P_Z="0.557414517406735" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="0.5866861452756388">
<NAME>Intraventricular haemorrhage</NAME>
<DICH_DATA CI_END="9.578327367462553" CI_START="0.29569282861349244" EFFECT_SIZE="1.6829268292682926" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9812896762493858" LOG_CI_START="-0.5291592082143461" LOG_EFFECT_SIZE="0.2260652340175198" ORDER="6" O_E="0.0" SE="0.8872451515765593" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.7872039589961116" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.077451873129563" CI_START="0.008714463444927201" DF="0.0" EFFECT_SIZE="0.16376306620209058" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.4881912699225436" LOG_CI_START="-2.059759347519093" LOG_EFFECT_SIZE="-0.7857840387982749" NO="2" P_CHI2="1.0" P_Z="0.22670138946988905" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="46" WEIGHT="100.0" Z="1.2088997370109515">
<NAME>Periventricular leukomalacia</NAME>
<DICH_DATA CI_END="3.0774518731295615" CI_START="0.008714463444927201" EFFECT_SIZE="0.16376306620209058" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4881912699225434" LOG_CI_START="-2.059759347519093" LOG_EFFECT_SIZE="-0.7857840387982749" ORDER="7" O_E="0.0" SE="1.4966788052441864" STUDY_ID="STD-Davis-2001" TOTAL_1="40" TOTAL_2="46" VAR="2.2400474460671655" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5982325795766872" CI_START="0.8112433995556511" DF="0.0" EFFECT_SIZE="1.138663967611336" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.2036399794065754" LOG_CI_START="-0.09084882368706919" LOG_EFFECT_SIZE="0.05639557785975312" NO="3" P_CHI2="1.0" P_Z="0.45284578286390353" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="45" WEIGHT="100.0" Z="0.7506791452257155">
<NAME>Retinopathy of prematurity</NAME>
<DICH_DATA CI_END="1.5982325795766874" CI_START="0.811243399555651" EFFECT_SIZE="1.138663967611336" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.20363997940657547" LOG_CI_START="-0.09084882368706926" LOG_EFFECT_SIZE="0.05639557785975312" ORDER="8" O_E="0.0" SE="0.1729841806802924" STUDY_ID="STD-Davis-2001" TOTAL_1="38" TOTAL_2="45" VAR="0.02992352676563204" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5762567011967907" CI_START="0.6599873837457839" DF="0.0" EFFECT_SIZE="1.0199556541019956" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.19762694591680943" LOG_CI_START="-0.1804643663095823" LOG_EFFECT_SIZE="0.008581289803613563" NO="4" P_CHI2="1.0" P_Z="0.9291073204310862" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.00000000000001" Z="0.08896802656979627">
<NAME>Sepsis: culture positive</NAME>
<DICH_DATA CI_END="1.576256701196791" CI_START="0.6599873837457838" EFFECT_SIZE="1.0199556541019956" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.1976269459168095" LOG_CI_START="-0.18046436630958235" LOG_EFFECT_SIZE="0.008581289803613563" ORDER="9" O_E="0.0" SE="0.22209270838396256" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.04932517111732383" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4364714760945725" CI_START="0.5980017750852963" DF="0.0" EFFECT_SIZE="0.926829268292683" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="0.15729700666091426" LOG_CI_START="-0.22329752686676485" LOG_EFFECT_SIZE="-0.03300026010292532" NO="5" P_CHI2="1.0" P_Z="0.7339426004207263" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="0.33988570819808595">
<NAME>Sepsis: suspected</NAME>
<DICH_DATA CI_END="1.4364714760945725" CI_START="0.5980017750852963" EFFECT_SIZE="0.926829268292683" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.15729700666091426" LOG_CI_START="-0.22329752686676485" LOG_EFFECT_SIZE="-0.03300026010292532" ORDER="10" O_E="0.0" SE="0.223563112967484" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.04998046547971201" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0693616718287338" CI_START="0.7598378233255199" DF="0.0" EFFECT_SIZE="1.2539454806312769" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" ID="CMP-001.04.06" LOG_CI_END="0.3158364009376415" LOG_CI_START="-0.11927909186485433" LOG_EFFECT_SIZE="0.0982786545363936" NO="6" P_CHI2="1.0" P_Z="0.37594838984132795" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="0.8853861860893065">
<NAME>Feeding intolerance: large or bilious gastric aspirates (in the 7 days after randomisation)</NAME>
<DICH_DATA CI_END="2.0693616718287338" CI_START="0.7598378233255199" EFFECT_SIZE="1.2539454806312769" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.3158364009376415" LOG_CI_START="-0.11927909186485433" LOG_EFFECT_SIZE="0.0982786545363936" ORDER="11" O_E="0.0" SE="0.25558899432861243" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.06532573402191148" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.842593266480563" CI_START="0.21118080988858998" DF="0.0" EFFECT_SIZE="2.2439024390243905" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.04.07" LOG_CI_END="1.3773534901651763" LOG_CI_START="-0.6753455489135366" LOG_EFFECT_SIZE="0.35100397062581984" NO="7" P_CHI2="1.0" P_Z="0.5026708824173138" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="0.6702932361345365">
<NAME>Necrotising enterocolitis</NAME>
<DICH_DATA CI_END="23.842593266480563" CI_START="0.21118080988858998" EFFECT_SIZE="2.2439024390243905" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3773534901651763" LOG_CI_START="-0.6753455489135366" LOG_EFFECT_SIZE="0.35100397062581984" ORDER="12" O_E="0.0" SE="1.2057655765789543" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="1.4538706256627782" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.7563328605925554" CI_START="-1.7563328605925554" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.47703673304263483" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="46" UNITS="" WEIGHT="100.0" Z="0.7110766673219221">
<NAME>Weight gain</NAME>
<GROUP_LABEL_1>Short binasal prong</GROUP_LABEL_1>
<GROUP_LABEL_2>Single nasal prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single nasal</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.7563328605925554" CI_START="-1.7563328605925554" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" NO="1" P_CHI2="1.0" P_Z="0.47703673304263483" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="0.7110766673219221">
<NAME>Weight gain from extubation to discharge (g/day)</NAME>
<CONT_DATA CI_END="3.7563328605925554" CI_START="-1.7563328605925554" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="20.0" ORDER="13" SD_1="7.0" SD_2="6.0" SE="1.4063181172379478" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.21074452666890353" CI_END="0.3435071355178483" CI_START="-8.805809632754015" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.231151248618083" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.8999894288902907" P_Q="0.8999894288902907" P_Z="0.06986391037515488" Q="0.21074452666890353" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="123" TOTAL_2="138" UNITS="" WEIGHT="300.0" Z="1.812791986652245">
<NAME>Days of respiratory support</NAME>
<GROUP_LABEL_1>Short binasal prong</GROUP_LABEL_1>
<GROUP_LABEL_2>Single nasal prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single nasal</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.3613546684658733" CI_START="-11.741354668465876" DF="0.0" EFFECT_SIZE="-4.190000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="1.0" P_Z="0.2768070892612755" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="1.0875199822777257">
<NAME>Total days on NCPAP</NAME>
<CONT_DATA CI_END="3.3613546684658733" CI_START="-11.741354668465876" EFFECT_SIZE="-4.190000000000001" ESTIMABLE="YES" MEAN_1="26.7" MEAN_2="30.89" ORDER="14" SD_1="16.59" SD_2="19.34" SE="3.8528027698620977" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.4445848153160306" CI_START="-10.224584815316028" DF="0.0" EFFECT_SIZE="-3.389999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="1.0" P_Z="0.3309733027888765" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="99.99999999999999" Z="0.9721553082055873">
<NAME>Total days intubated</NAME>
<CONT_DATA CI_END="3.4445848153160297" CI_START="-10.224584815316028" EFFECT_SIZE="-3.389999999999999" ESTIMABLE="YES" MEAN_1="13.85" MEAN_2="17.24" ORDER="15" SD_1="14.82" SD_2="17.69" SE="3.487097145267138" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.286348259750119" CI_START="-16.986348259750123" DF="0.0" EFFECT_SIZE="-6.350000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.03" NO="3" P_CHI2="1.0" P_Z="0.24195393178086133" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="1.1701169421958864">
<NAME>Total days of respiratory support (NCPAP and intubation)</NAME>
<CONT_DATA CI_END="4.286348259750119" CI_START="-16.986348259750123" EFFECT_SIZE="-6.350000000000001" ESTIMABLE="YES" MEAN_1="39.93" MEAN_2="46.28" ORDER="16" SD_1="24.68" SD_2="25.91" SE="5.426808014661635" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="14.206345410579665" CI_START="-23.446345410579674" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.6200000000000045" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.6305330558097517" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="46" UNITS="" WEIGHT="100.0" Z="0.4809767063705569">
<NAME>Resource utilisation</NAME>
<GROUP_LABEL_1>Short binasal prong</GROUP_LABEL_1>
<GROUP_LABEL_2>Single nasal prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single nasal</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.206345410579665" CI_START="-23.446345410579674" DF="0.0" EFFECT_SIZE="-4.6200000000000045" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="0.6305330558097517" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="0.4809767063705569">
<NAME>Total days in level III hospital</NAME>
<CONT_DATA CI_END="14.206345410579665" CI_START="-23.446345410579674" EFFECT_SIZE="-4.6200000000000045" ESTIMABLE="YES" MEAN_1="77.1" MEAN_2="81.72" ORDER="17" SD_1="35.5" SD_2="53.2" SE="9.605454773189447" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Infant Flow Driver (short binasal) vs Medicorp prong (short binasal) NCPAP to prevent extubation failure</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6696125655694652" CI_START="0.16593343199379443" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.17417640521450153" LOG_CI_START="-0.7800661042248235" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.002023005033386337" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="3.0868340459875316">
<NAME>Extubation failure</NAME>
<GROUP_LABEL_1>Infant Flow Driver</GROUP_LABEL_1>
<GROUP_LABEL_2>Medicorp prongs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Flow Driver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Medicorp</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6696125655694652" CI_START="0.16593343199379443" DF="0.0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="24" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.17417640521450153" LOG_CI_START="-0.7800661042248235" LOG_EFFECT_SIZE="-0.4771212547196625" NO="1" P_CHI2="1.0" P_Z="0.002023005033386337" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="3.0868340459875316">
<NAME>Endotracheal intubation within 7 days post-extubation</NAME>
<DICH_DATA CI_END="0.6696125655694652" CI_START="0.16593343199379443" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="24" LOG_CI_END="-0.17417640521450153" LOG_CI_START="-0.7800661042248235" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="18" O_E="0.0" SE="0.3559026084010437" STUDY_ID="STD-Sun-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.12666666666666668" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Infant Flow Driver</GROUP_LABEL_1>
<GROUP_LABEL_2>Medicorp prongs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Flow Driver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Medicorp</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="19" O_E="0.0" SE="0.0" STUDY_ID="STD-Sun-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8976950170217486" CI_END="1.010829635624512" CI_START="0.3908690711983569" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6285714285714286" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.004677966132246656" LOG_CI_START="-0.40796869318838547" LOG_EFFECT_SIZE="-0.2016453635280694" METHOD="MH" NO="3" P_CHI2="0.4076691679502412" P_Q="0.0" P_Z="0.05542548885968216" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="200" TOTAL_2="200" WEIGHT="400.0" Z="1.915525746968004">
<NAME>Pulmonary outcomes</NAME>
<GROUP_LABEL_1>Infant Flow Driver</GROUP_LABEL_1>
<GROUP_LABEL_2>Medicorp prongs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Flow Driver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Medicorp</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0919370882132886" CI_START="0.3296893235754632" DF="0.0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.0381976172799971" LOG_CI_START="-0.4818951165127098" LOG_EFFECT_SIZE="-0.22184874961635637" NO="1" P_CHI2="1.0" P_Z="0.09451064798545791" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="1.6720693484504896">
<NAME>Chronic lung disease: supplemental oxygen at day 28 of life</NAME>
<DICH_DATA CI_END="1.0919370882132886" CI_START="0.3296893235754632" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="0.0381976172799971" LOG_CI_START="-0.4818951165127098" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="20" O_E="0.0" SE="0.30550504633038933" STUDY_ID="STD-Sun-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.09333333333333332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3711569500113296" CI_START="0.30984616077291294" DF="0.0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.374960301455169" LOG_CI_START="-0.5088538807163954" LOG_EFFECT_SIZE="-0.06694678963061322" NO="2" P_CHI2="1.0" P_Z="0.7665237116586479" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.29692507588910944">
<NAME>Chronic lung disease: supplemental oxygen at corrected gestational age of 36 weeks</NAME>
<DICH_DATA CI_END="2.3711569500113296" CI_START="0.30984616077291294" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.374960301455169" LOG_CI_START="-0.5088538807163954" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="21" O_E="0.0" SE="0.519156825558337" STUDY_ID="STD-Sun-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.2695238095238095" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3346052970893525" CI_START="0.020813477841245254" DF="0.0" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="0.12535284424629042" LOG_CI_START="-1.6816553450135776" LOG_EFFECT_SIZE="-0.7781512503836436" NO="3" P_CHI2="1.0" P_Z="0.09140410878404913" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="1.68803709284952">
<NAME>Chronic lung disease: home oxygen therapy</NAME>
<DICH_DATA CI_END="1.3346052970893525" CI_START="0.020813477841245254" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.12535284424629042" LOG_CI_START="-1.6816553450135776" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="22" O_E="0.0" SE="1.0614455552060438" STUDY_ID="STD-Sun-1999" TOTAL_1="50" TOTAL_2="50" VAR="1.1266666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.59508521794332" CI_START="0.2617775092331654" DF="0.0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-002.03.04" LOG_CI_END="0.9342501869566456" LOG_CI_START="-0.582067668845283" LOG_EFFECT_SIZE="0.17609125905568124" NO="4" P_CHI2="1.0" P_Z="0.6489477312144929" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.4552245090577255">
<NAME>Air leak</NAME>
<DICH_DATA CI_END="8.59508521794332" CI_START="0.2617775092331654" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9342501869566456" LOG_CI_START="-0.582067668845283" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="23" O_E="0.0" SE="0.8906926143924925" STUDY_ID="STD-Sun-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.7933333333333332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1778442673524767" CI_END="1.8657380665668208" CI_START="0.5359809171070399" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.2708506725136554" LOG_CI_START="-0.2708506725136554" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="4" P_CHI2="0.6732324313201463" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" WEIGHT="200.0" Z="0.0">
<NAME>Non-pulmonary outcomes</NAME>
<GROUP_LABEL_1>Infant Flow Driver</GROUP_LABEL_1>
<GROUP_LABEL_2>Medicorp prongs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Flow Driver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Medicorp</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.236975432315035" CI_START="0.5320052368194711" DF="0.0" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.3496612144638166" LOG_CI_START="-0.2740840926850171" LOG_EFFECT_SIZE="0.037788560889399754" NO="1" P_CHI2="1.0" P_Z="0.8122826908063876" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.00000000000001" Z="0.23748224642963037">
<NAME>Culture positive sepsis</NAME>
<DICH_DATA CI_END="2.2369754323150355" CI_START="0.532005236819471" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.34966121446381665" LOG_CI_START="-0.27408409268501716" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="24" O_E="0.0" SE="0.3663910810082913" STUDY_ID="STD-Sun-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.13424242424242427" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8062406427651023" CI_START="0.2280631212615402" DF="0.0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.44812491022187245" LOG_CI_START="-0.6419449362379852" LOG_EFFECT_SIZE="-0.09691001300805639" NO="2" P_CHI2="1.0" P_Z="0.7274709628735369" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.34849167849923335">
<NAME>Necrotising enterocolitis</NAME>
<DICH_DATA CI_END="2.8062406427651023" CI_START="0.2280631212615402" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.44812491022187245" LOG_CI_START="-0.6419449362379852" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="25" O_E="0.0" SE="0.6403124237432849" STUDY_ID="STD-Sun-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.41" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.931698825995092" CI_START="-3.731698825995089" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6554443581017928" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="50" UNITS="" WEIGHT="99.99999999999999" Z="0.44621166604895773">
<NAME>Days of respiratory support</NAME>
<GROUP_LABEL_1>Infant Flow Driver</GROUP_LABEL_1>
<GROUP_LABEL_2>Medicorp prongs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Flow Driver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Medicorp</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.931698825995092" CI_START="-3.731698825995089" DF="0.0" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.01" NO="1" P_CHI2="1.0" P_Z="0.6554443581017928" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.44621166604895773">
<NAME>Total days of NCPAP</NAME>
<CONT_DATA CI_END="5.931698825995092" CI_START="-3.731698825995089" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="11.7" ORDER="26" SD_1="13.1" SD_2="11.5" SE="2.465197760829747" STUDY_ID="STD-Sun-1999" TOTAL_1="50" TOTAL_2="50" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Short binasal prong (Infant Flow Driver) vs nasopharyngeal prong CPAP to prevent extubation failure</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="48" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Extubation failure</NAME>
<GROUP_LABEL_1>Short binasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Nasopharyngeal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nasophar.</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="27" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Endotracheal intubation within 7 days post-extubation</NAME>
<DICH_DATA CI_END="0.9667879781411749" CI_START="0.40404412221906955" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="27" LOG_CI_END="-0.01466875861545381" LOG_CI_START="-0.3935712066963957" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="27" O_E="0.0" SE="0.22256917360011255" STUDY_ID="STD-Roukema-1999a" TOTAL_1="48" TOTAL_2="45" VAR="0.04953703703703703" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Short binasal prong vs single prong (nasal or nasopharyngeal) NCPAP to prevent extubation failure</NAME>
<DICH_OUTCOME CHI2="0.992716790293525" CI_END="0.7311823866256368" CI_START="0.38956180732012585" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5337047236202113" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="72" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.13597427882157942" LOG_CI_START="-0.40942362798228527" LOG_EFFECT_SIZE="-0.27269895340193234" METHOD="MH" NO="1" P_CHI2="0.608743490134291" P_Q="0.0" P_Z="9.26134073350091E-5" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="130" TOTAL_2="137" WEIGHT="200.0" Z="3.909170959302161">
<NAME>Extubation failure</NAME>
<GROUP_LABEL_1>Short binasal prong</GROUP_LABEL_1>
<GROUP_LABEL_2>Single prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single prong</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.16161157611343674" CI_END="0.8523906753264693" CI_START="0.4061756448573271" DF="1.0" EFFECT_SIZE="0.5884049049940875" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="46" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-0.06936130986868773" LOG_CI_START="-0.3912861213575565" LOG_EFFECT_SIZE="-0.23032371561312215" NO="1" P_CHI2="0.6876773082419287" P_Z="0.005038777270140002" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="91" WEIGHT="100.0" Z="2.804544236894112">
<NAME>Endotracheal intubation within 7 days post-extubation</NAME>
<DICH_DATA CI_END="1.0408322293860992" CI_START="0.2713595030254182" EFFECT_SIZE="0.5314505776636713" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" LOG_CI_END="0.017380731697098657" LOG_CI_START="-0.5664549648004298" LOG_EFFECT_SIZE="-0.27453711655166557" ORDER="28" O_E="0.0" SE="0.34294797815595573" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.1176133157212579" WEIGHT="39.118461762752496"/>
<DICH_DATA CI_END="0.9667879781411749" CI_START="0.40404412221906955" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="27" LOG_CI_END="-0.01466875861545381" LOG_CI_START="-0.3935712066963957" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="29" O_E="0.0" SE="0.22256917360011255" STUDY_ID="STD-Roukema-1999a" TOTAL_1="48" TOTAL_2="45" VAR="0.04953703703703703" WEIGHT="60.881538237247504"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7827958220323943" CI_START="0.2378771655202614" DF="0.0" EFFECT_SIZE="0.43151969981238275" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-0.10635150094086174" LOG_CI_START="-0.623647245077097" LOG_EFFECT_SIZE="-0.3649993730089794" NO="2" P_CHI2="1.0" P_Z="0.0056771675996245986" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="2.7658670444769657">
<NAME>Respiratory failure within 7 days post-extubation</NAME>
<DICH_DATA CI_END="0.7827958220323943" CI_START="0.23787716552026134" EFFECT_SIZE="0.43151969981238275" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" LOG_CI_END="-0.10635150094086174" LOG_CI_START="-0.6236472450770971" LOG_EFFECT_SIZE="-0.3649993730089794" ORDER="30" O_E="0.0" SE="0.3038620807608558" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.09233216412431684" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Short binasal prong</GROUP_LABEL_1>
<GROUP_LABEL_2>Single prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single prong</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.578327367462553" CI_START="0.29569282861349244" EFFECT_SIZE="1.6829268292682926" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9812896762493858" LOG_CI_START="-0.5291592082143461" LOG_EFFECT_SIZE="0.2260652340175198" ORDER="31" O_E="0.0" SE="0.8872451515765593" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.7872039589961116" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05551700248664902" CI_END="1.0550794430462977" CI_START="0.6492742003644916" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8276689324270291" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.0232851614135072" LOG_CI_START="-0.1875718539606768" LOG_EFFECT_SIZE="-0.08214334627358481" METHOD="MH" NO="3" P_CHI2="0.8137271953004357" P_Q="0.0" P_Z="0.1267405659201516" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="92" WEIGHT="200.0" Z="1.5270822265991368">
<NAME>Chronic lung disease</NAME>
<GROUP_LABEL_1>Short binasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Single prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single prong</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.967061114426712E-31" CI_END="1.1527731028984272" CI_START="0.626695033214888" DF="0.0" EFFECT_SIZE="0.8499630450849962" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="33" I2="100.0" ID="CMP-004.03.01" LOG_CI_END="0.06174383473942711" LOG_CI_START="-0.2029437472274498" LOG_EFFECT_SIZE="-0.07059995624401133" NO="1" P_CHI2="0.0" P_Z="0.2957642492563691" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="1.045559980714789">
<NAME>Supplemental oxygen at day 28 of life</NAME>
<DICH_DATA CI_END="1.1527731028984274" CI_START="0.6266950332148881" EFFECT_SIZE="0.8499630450849963" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="33" LOG_CI_END="0.06174383473942719" LOG_CI_START="-0.20294374722744973" LOG_EFFECT_SIZE="-0.07059995624401127" ORDER="32" O_E="0.0" SE="0.15547879587200525" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.02417365596580868" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1835882203339612" CI_START="0.5426143118034259" DF="0.0" EFFECT_SIZE="0.8013937282229965" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="28" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.07320063419270408" LOG_CI_START="-0.26550875562550297" LOG_EFFECT_SIZE="-0.09615406071639947" NO="2" P_CHI2="1.0" P_Z="0.26579285298210686" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="1.1128034925312846">
<NAME>Supplemental oxygen at corrected gestational age of 36 weeks</NAME>
<DICH_DATA CI_END="1.1835882203339612" CI_START="0.5426143118034259" EFFECT_SIZE="0.8013937282229965" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="28" LOG_CI_END="0.07320063419270408" LOG_CI_START="-0.26550875562550297" LOG_EFFECT_SIZE="-0.09615406071639947" ORDER="33" O_E="0.0" SE="0.19895957221773494" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.03958491137706408" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.189925709143573" CI_END="1.3160120577447565" CI_START="0.8653245995291248" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0671352336248114" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.11925986844816622" LOG_CI_START="-0.06282094994508526" LOG_EFFECT_SIZE="0.028219459251540496" METHOD="MH" NO="4" P_CHI2="0.7846595340390234" P_Q="0.0" P_Z="0.5435040233619546" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="283" TOTAL_2="321" WEIGHT="700.0" Z="0.6075227943754118">
<NAME>Non-pulmonary outcomes</NAME>
<GROUP_LABEL_1>Short binasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Single nasal prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single prong</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.578327367462556" CI_START="0.2956928286134924" DF="0.0" EFFECT_SIZE="1.6829268292682926" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.9812896762493859" LOG_CI_START="-0.5291592082143463" LOG_EFFECT_SIZE="0.2260652340175198" NO="1" P_CHI2="1.0" P_Z="0.557414517406735" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="0.5866861452756388">
<NAME>Intraventricular haemorrhage</NAME>
<DICH_DATA CI_END="9.578327367462553" CI_START="0.29569282861349244" EFFECT_SIZE="1.6829268292682926" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9812896762493858" LOG_CI_START="-0.5291592082143461" LOG_EFFECT_SIZE="0.2260652340175198" ORDER="34" O_E="0.0" SE="0.8872451515765593" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.7872039589961116" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.077451873129563" CI_START="0.008714463444927201" DF="0.0" EFFECT_SIZE="0.16376306620209058" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="0.4881912699225436" LOG_CI_START="-2.059759347519093" LOG_EFFECT_SIZE="-0.7857840387982749" NO="2" P_CHI2="1.0" P_Z="0.22670138946988905" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="46" WEIGHT="100.0" Z="1.2088997370109515">
<NAME>Periventricular leukomalacia</NAME>
<DICH_DATA CI_END="3.0774518731295615" CI_START="0.008714463444927201" EFFECT_SIZE="0.16376306620209058" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4881912699225434" LOG_CI_START="-2.059759347519093" LOG_EFFECT_SIZE="-0.7857840387982749" ORDER="35" O_E="0.0" SE="1.4966788052441864" STUDY_ID="STD-Davis-2001" TOTAL_1="40" TOTAL_2="46" VAR="2.2400474460671655" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5982325795766872" CI_START="0.8112433995556511" DF="0.0" EFFECT_SIZE="1.138663967611336" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="0.2036399794065754" LOG_CI_START="-0.09084882368706919" LOG_EFFECT_SIZE="0.05639557785975312" NO="3" P_CHI2="1.0" P_Z="0.45284578286390353" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="45" WEIGHT="100.0" Z="0.7506791452257155">
<NAME>Retinopathy of prematurity</NAME>
<DICH_DATA CI_END="1.5982325795766874" CI_START="0.811243399555651" EFFECT_SIZE="1.138663967611336" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.20363997940657547" LOG_CI_START="-0.09084882368706926" LOG_EFFECT_SIZE="0.05639557785975312" ORDER="36" O_E="0.0" SE="0.1729841806802924" STUDY_ID="STD-Davis-2001" TOTAL_1="38" TOTAL_2="45" VAR="0.02992352676563204" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5762567011967907" CI_START="0.6599873837457839" DF="0.0" EFFECT_SIZE="1.0199556541019956" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="0.0" ID="CMP-004.04.04" LOG_CI_END="0.19762694591680943" LOG_CI_START="-0.1804643663095823" LOG_EFFECT_SIZE="0.008581289803613563" NO="4" P_CHI2="1.0" P_Z="0.9291073204310862" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.00000000000001" Z="0.08896802656979627">
<NAME>Sepsis: culture positive</NAME>
<DICH_DATA CI_END="1.576256701196791" CI_START="0.6599873837457838" EFFECT_SIZE="1.0199556541019956" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.1976269459168095" LOG_CI_START="-0.18046436630958235" LOG_EFFECT_SIZE="0.008581289803613563" ORDER="37" O_E="0.0" SE="0.22209270838396256" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.04932517111732383" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4364714760945725" CI_START="0.5980017750852963" DF="0.0" EFFECT_SIZE="0.926829268292683" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="0.0" ID="CMP-004.04.05" LOG_CI_END="0.15729700666091426" LOG_CI_START="-0.22329752686676485" LOG_EFFECT_SIZE="-0.03300026010292532" NO="5" P_CHI2="1.0" P_Z="0.7339426004207263" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="0.33988570819808595">
<NAME>Sepsis: suspected</NAME>
<DICH_DATA CI_END="1.4364714760945725" CI_START="0.5980017750852963" EFFECT_SIZE="0.926829268292683" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.15729700666091426" LOG_CI_START="-0.22329752686676485" LOG_EFFECT_SIZE="-0.03300026010292532" ORDER="38" O_E="0.0" SE="0.223563112967484" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.04998046547971201" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0693616718287338" CI_START="0.7598378233255199" DF="0.0" EFFECT_SIZE="1.2539454806312769" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" ID="CMP-004.04.06" LOG_CI_END="0.3158364009376415" LOG_CI_START="-0.11927909186485433" LOG_EFFECT_SIZE="0.0982786545363936" NO="6" P_CHI2="1.0" P_Z="0.37594838984132795" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="0.8853861860893065">
<NAME>Feeding intolerance: large or bilious gastric aspirates (in the 7 days following randomisation)</NAME>
<DICH_DATA CI_END="2.0693616718287338" CI_START="0.7598378233255199" EFFECT_SIZE="1.2539454806312769" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.3158364009376415" LOG_CI_START="-0.11927909186485433" LOG_EFFECT_SIZE="0.0982786545363936" ORDER="39" O_E="0.0" SE="0.25558899432861243" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="0.06532573402191148" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.842593266480563" CI_START="0.21118080988858998" DF="0.0" EFFECT_SIZE="2.2439024390243905" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.04.07" LOG_CI_END="1.3773534901651763" LOG_CI_START="-0.6753455489135366" LOG_EFFECT_SIZE="0.35100397062581984" NO="7" P_CHI2="1.0" P_Z="0.5026708824173138" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="0.6702932361345365">
<NAME>Necrotising enterocolitis</NAME>
<DICH_DATA CI_END="23.842593266480563" CI_START="0.21118080988858998" EFFECT_SIZE="2.2439024390243905" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3773534901651763" LOG_CI_START="-0.6753455489135366" LOG_EFFECT_SIZE="0.35100397062581984" ORDER="40" O_E="0.0" SE="1.2057655765789543" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" VAR="1.4538706256627782" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.7563328605925554" CI_START="-1.7563328605925554" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.47703673304263483" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="46" UNITS="" WEIGHT="100.0" Z="0.7110766673219221">
<NAME>Weight gain</NAME>
<GROUP_LABEL_1>Short binasal prong</GROUP_LABEL_1>
<GROUP_LABEL_2>Single prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single prong</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.7563328605925554" CI_START="-1.7563328605925554" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.01" NO="1" P_CHI2="1.0" P_Z="0.47703673304263483" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="0.7110766673219221">
<NAME>Weight gain from extubation to discharge (g/day)</NAME>
<CONT_DATA CI_END="3.7563328605925554" CI_START="-1.7563328605925554" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="20.0" ORDER="41" SD_1="7.0" SD_2="6.0" SE="1.4063181172379478" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.21074452666890353" CI_END="0.3435071355178483" CI_START="-8.805809632754015" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.231151248618083" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.06" NO="6" P_CHI2="0.8999894288902907" P_Q="0.8999894288902907" P_Z="0.06986391037515488" Q="0.21074452666890353" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="123" TOTAL_2="138" UNITS="" WEIGHT="300.0" Z="1.812791986652245">
<NAME>Days of respiratory support</NAME>
<GROUP_LABEL_1>Short binasal prong</GROUP_LABEL_1>
<GROUP_LABEL_2>Single prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single prong</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.3613546684658733" CI_START="-11.741354668465876" DF="0.0" EFFECT_SIZE="-4.190000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.01" NO="1" P_CHI2="1.0" P_Z="0.2768070892612755" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="1.0875199822777257">
<NAME>Total days on NCPAP</NAME>
<CONT_DATA CI_END="3.3613546684658733" CI_START="-11.741354668465876" EFFECT_SIZE="-4.190000000000001" ESTIMABLE="YES" MEAN_1="26.7" MEAN_2="30.89" ORDER="42" SD_1="16.59" SD_2="19.34" SE="3.8528027698620977" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.4445848153160306" CI_START="-10.224584815316028" DF="0.0" EFFECT_SIZE="-3.389999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.02" NO="2" P_CHI2="1.0" P_Z="0.3309733027888765" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="99.99999999999999" Z="0.9721553082055873">
<NAME>Total days intubated</NAME>
<CONT_DATA CI_END="3.4445848153160297" CI_START="-10.224584815316028" EFFECT_SIZE="-3.389999999999999" ESTIMABLE="YES" MEAN_1="13.85" MEAN_2="17.24" ORDER="43" SD_1="14.82" SD_2="17.69" SE="3.487097145267138" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.286348259750119" CI_START="-16.986348259750123" DF="0.0" EFFECT_SIZE="-6.350000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.03" NO="3" P_CHI2="1.0" P_Z="0.24195393178086133" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="1.1701169421958864">
<NAME>Total days of respiratory support (NCPAP and intubation)</NAME>
<CONT_DATA CI_END="4.286348259750119" CI_START="-16.986348259750123" EFFECT_SIZE="-6.350000000000001" ESTIMABLE="YES" MEAN_1="39.93" MEAN_2="46.28" ORDER="44" SD_1="24.68" SD_2="25.91" SE="5.426808014661635" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="14.206345410579665" CI_START="-23.446345410579674" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.6200000000000045" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.6305330558097517" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="46" UNITS="" WEIGHT="100.0" Z="0.4809767063705569">
<NAME>Resource utilisation</NAME>
<GROUP_LABEL_1>Short binasal prong</GROUP_LABEL_1>
<GROUP_LABEL_2>Single prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single prong</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.206345410579665" CI_START="-23.446345410579674" DF="0.0" EFFECT_SIZE="-4.6200000000000045" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.01" NO="1" P_CHI2="1.0" P_Z="0.6305330558097517" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0" Z="0.4809767063705569">
<NAME>Total days in level III hospital</NAME>
<CONT_DATA CI_END="14.206345410579665" CI_START="-23.446345410579674" EFFECT_SIZE="-4.6200000000000045" ESTIMABLE="YES" MEAN_1="77.1" MEAN_2="81.72" ORDER="45" SD_1="35.5" SD_2="53.2" SE="9.605454773189447" STUDY_ID="STD-Davis-2001" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Infant Flow Driver (short binasal) vs INCA prong (short binasal) to prevent extubation failure</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4931173711768737" CI_START="0.6826812443074327" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0096153846153846" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.17409394814761495" LOG_CI_START="-0.16578202860529953" LOG_EFFECT_SIZE="0.004155959771157703" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.9617701371062334" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="84" WEIGHT="100.0" Z="0.04793237551230708">
<NAME>Endotracheal intubation within 7 days post-extubation</NAME>
<GROUP_LABEL_1>Infant Flow Driver</GROUP_LABEL_1>
<GROUP_LABEL_2>INCA prongs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Infant Flow</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INCA prongs</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4931173711768735" CI_START="0.6826812443074327" EFFECT_SIZE="1.0096153846153846" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.1740939481476149" LOG_CI_START="-0.16578202860529953" LOG_EFFECT_SIZE="0.004155959771157703" ORDER="46" O_E="0.0" SE="0.19964483115788048" STUDY_ID="STD-Stefanescu-2003" TOTAL_1="78" TOTAL_2="84" VAR="0.039858058608058605" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.439037546094216" CI_START="0.7900350726061933" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.871794871794872" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="1.0186604596156175" LOG_CI_START="-0.10235362832825273" LOG_EFFECT_SIZE="0.4581534156436824" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.1091430210118024" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="84" WEIGHT="99.99999999999999" Z="1.6020569299046827">
<NAME>Death</NAME>
<GROUP_LABEL_1>Infant Flow Driver</GROUP_LABEL_1>
<GROUP_LABEL_2>INCA prongs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Infant Flow</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INCA prongs</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.439037546094216" CI_START="0.7900350726061933" EFFECT_SIZE="2.871794871794872" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0186604596156175" LOG_CI_START="-0.10235362832825273" LOG_EFFECT_SIZE="0.4581534156436824" ORDER="47" O_E="0.0" SE="0.6584892243674596" STUDY_ID="STD-Stefanescu-2003" TOTAL_1="78" TOTAL_2="84" VAR="0.43360805860805857" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.138876678407921" CI_START="0.6517373959643082" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8615384615384616" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.05647669968353105" LOG_CI_START="-0.18592735895684126" LOG_EFFECT_SIZE="-0.06472532963665513" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.2952488242443816" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="84" WEIGHT="100.0" Z="1.046676492851417">
<NAME>Chronic lung disease</NAME>
<GROUP_LABEL_1>Infant Flow Driver</GROUP_LABEL_1>
<GROUP_LABEL_2>INCA prongs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Infant Flow</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INCA prong</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.138876678407921" CI_START="0.6517373959643082" DF="0.0" EFFECT_SIZE="0.8615384615384616" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="50" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.05647669968353105" LOG_CI_START="-0.18592735895684126" LOG_EFFECT_SIZE="-0.06472532963665513" NO="1" P_CHI2="1.0" P_Z="0.2952488242443816" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="84" WEIGHT="100.0" Z="1.046676492851417">
<NAME>Supplemental oxygen and CXR changes at corrected gestational age of 36 weeks</NAME>
<DICH_DATA CI_END="1.138876678407921" CI_START="0.6517373959643082" EFFECT_SIZE="0.8615384615384616" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="50" LOG_CI_END="0.05647669968353105" LOG_CI_START="-0.18592735895684126" LOG_EFFECT_SIZE="-0.06472532963665513" ORDER="48" O_E="0.0" SE="0.14238934396479702" STUDY_ID="STD-Stefanescu-2003" TOTAL_1="78" TOTAL_2="84" VAR="0.020274725274725278" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.50936409200061" CI_START="0.6071140841789088" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9572649572649573" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.1787940138470519" LOG_CI_START="-0.21672969199901196" LOG_EFFECT_SIZE="-0.01896783907598001" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.8508883324929165" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="84" WEIGHT="100.0" Z="0.18798509876392175">
<NAME>PIE and gross air leak</NAME>
<GROUP_LABEL_1>Infant Flow Driver</GROUP_LABEL_1>
<GROUP_LABEL_2>INCA prongs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Infant Flow</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INCA prongs</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.50936409200061" CI_START="0.6071140841789088" EFFECT_SIZE="0.9572649572649573" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.1787940138470519" LOG_CI_START="-0.21672969199901196" LOG_EFFECT_SIZE="-0.01896783907598001" ORDER="49" O_E="0.0" SE="0.23233258268789803" STUDY_ID="STD-Stefanescu-2003" TOTAL_1="78" TOTAL_2="84" VAR="0.05397842897842897" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="158" EVENTS_2="176" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="390" TOTAL_2="420" WEIGHT="0.0" Z="0.0">
<NAME>Non-pulmonary outcomes</NAME>
<GROUP_LABEL_1>Infant Flow Driver</GROUP_LABEL_1>
<GROUP_LABEL_2>INCA prongs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Infant Flow</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INCA prongs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="15" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="84" WEIGHT="0.0" Z="0.0">
<NAME>Necrotising enterocolitis</NAME>
<DICH_DATA CI_END="2.3831389535270997" CI_START="0.700781282235309" EFFECT_SIZE="1.2923076923076924" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.3771493654646723" LOG_CI_START="-0.15441750662662007" LOG_EFFECT_SIZE="0.11136592941902611" ORDER="50" O_E="0.0" SE="0.3122450119648791" STUDY_ID="STD-Stefanescu-2003" TOTAL_1="78" TOTAL_2="84" VAR="0.0974969474969475" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="66" EVENTS_2="70" I2="0.0" ID="CMP-005.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="84" WEIGHT="0.0" Z="0.0">
<NAME>Sepsis: culture positive and suspected combined</NAME>
<DICH_DATA CI_END="1.1616095789362746" CI_START="0.8875666453300862" EFFECT_SIZE="1.0153846153846153" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="70" LOG_CI_END="0.06506018467662279" LOG_CI_START="-0.05179902687859664" LOG_EFFECT_SIZE="0.006630578899013076" ORDER="51" O_E="0.0" SE="0.06864367932996243" STUDY_ID="STD-Stefanescu-2003" TOTAL_1="78" TOTAL_2="84" VAR="0.004711954711954711" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="14" I2="0.0" ID="CMP-005.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="84" WEIGHT="0.0" Z="0.0">
<NAME>Intraventricular haemorrhage: grade 3 and 4</NAME>
<DICH_DATA CI_END="1.7507022115088706" CI_START="0.40896522929726076" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.24321228035131248" LOG_CI_START="-0.3883136146485359" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="52" O_E="0.0" SE="0.3709614368265084" STUDY_ID="STD-Stefanescu-2003" TOTAL_1="78" TOTAL_2="84" VAR="0.1376123876123876" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-005.05.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="84" WEIGHT="0.0" Z="0.0">
<NAME>Periventricular leukomalacia</NAME>
<DICH_DATA CI_END="2.61447994664342" CI_START="0.1596932473838369" EFFECT_SIZE="0.6461538461538462" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4173853150907056" LOG_CI_START="-0.7967134475806157" LOG_EFFECT_SIZE="-0.18966406624495508" ORDER="53" O_E="0.0" SE="0.7131676230789356" STUDY_ID="STD-Stefanescu-2003" TOTAL_1="78" TOTAL_2="84" VAR="0.5086080586080587" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="60" EVENTS_2="72" I2="0.0" ID="CMP-005.05.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="84" WEIGHT="0.0" Z="0.0">
<NAME>Retinopathy of prematurity: all grades</NAME>
<DICH_DATA CI_END="1.0423126701228287" CI_START="0.7726963444775793" EFFECT_SIZE="0.8974358974358975" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="72" LOG_CI_END="0.01799801698641323" LOG_CI_START="-0.11199114233886032" LOG_EFFECT_SIZE="-0.046996562676223555" ORDER="54" O_E="0.0" SE="0.07635627564438191" STUDY_ID="STD-Stefanescu-2003" TOTAL_1="78" TOTAL_2="84" VAR="0.00583028083028083" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1216741321681183" CI_START="-3.9816741321681177" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4299999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.2720316532894437" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="84" UNITS="" WEIGHT="100.0" Z="1.0983959364399032">
<NAME>Total days of NCPAP</NAME>
<GROUP_LABEL_1>Infant Flow Driver</GROUP_LABEL_1>
<GROUP_LABEL_2>INCA prongs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Infant Flow</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INCA prongs</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1216741321681183" CI_START="-3.9816741321681177" EFFECT_SIZE="-1.4299999999999997" ESTIMABLE="YES" MEAN_1="8.74" MEAN_2="10.17" ORDER="55" SD_1="8.04" SD_2="8.53" SE="1.3018984799187117" STUDY_ID="STD-Stefanescu-2003" TOTAL_1="78" TOTAL_2="84" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.2579365933504576" CI_START="-21.742063406649542" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.027758120381004413" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="84" UNITS="" WEIGHT="100.0" Z="2.200687979296931">
<NAME>Days in oxygen</NAME>
<GROUP_LABEL_1>Infant Flow Driver</GROUP_LABEL_1>
<GROUP_LABEL_2>INCA prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Infant Flow</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INCA prong</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.2579365933504594" CI_START="-21.742063406649542" EFFECT_SIZE="-11.5" ESTIMABLE="YES" MEAN_1="65.7" MEAN_2="77.2" ORDER="56" SD_1="31.4" SD_2="35.1" SE="5.2256385767481595" STUDY_ID="STD-Stefanescu-2003" TOTAL_1="78" TOTAL_2="84" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.385851721891523" CI_START="-22.814148278108465" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-12.599999999999994" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.015615587116320542" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="84" UNITS="" WEIGHT="100.0" Z="2.4177783142362967">
<NAME>Resource utilisation</NAME>
<GROUP_LABEL_1>Infant Flow Driver</GROUP_LABEL_1>
<GROUP_LABEL_2>INCA prongs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Infant Flow</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INCA prongs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.385851721891523" CI_START="-22.814148278108465" DF="0.0" EFFECT_SIZE="-12.599999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-005.08.01" NO="1" P_CHI2="1.0" P_Z="0.015615587116320542" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="84" WEIGHT="100.0" Z="2.4177783142362967">
<NAME>Total days in hospital</NAME>
<CONT_DATA CI_END="-2.385851721891523" CI_START="-22.814148278108465" EFFECT_SIZE="-12.599999999999994" ESTIMABLE="YES" MEAN_1="73.7" MEAN_2="86.3" ORDER="57" SD_1="28.7" SD_2="37.34" SE="5.211395902514724" STUDY_ID="STD-Stefanescu-2003" TOTAL_1="78" TOTAL_2="84" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Short binasal prong vs nasopharyngeal (single tube) CPAP for early respiratory distress</NAME>
<DICH_OUTCOME CHI2="0.1337941412099725" CI_END="0.8949050697849781" CI_START="0.06334676639752308" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-0.04822303156135936" LOG_CI_START="-1.1982755492344417" LOG_EFFECT_SIZE="-0.6232492903979004" METHOD="MH" NO="1" P_CHI2="0.9352914759271558" P_Q="0.0" P_Z="0.033642467261689984" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="54" TOTAL_2="54" WEIGHT="300.0" Z="2.1243310958383055">
<NAME>Treatment failure</NAME>
<GROUP_LABEL_1>Short binasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Nasopharyngeal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nasophar.</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.910163963500591" CI_START="0.03818036114276435" DF="0.0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.4639174585520589" LOG_CI_START="-1.4181599679913839" LOG_EFFECT_SIZE="-0.4771212547196625" NO="1" P_CHI2="1.0" P_Z="0.32035327265813984" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="0.993732204977928">
<NAME>Endotracheal intubation within 48 hours of randomisation</NAME>
<DICH_DATA CI_END="2.910163963500591" CI_START="0.03818036114276435" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4639174585520589" LOG_CI_START="-1.4181599679913839" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="58" O_E="0.0" SE="1.1055415967851332" STUDY_ID="STD-Mazzella-2001" TOTAL_1="18" TOTAL_2="18" VAR="1.222222222222222" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5461706858829376" CI_START="0.025870365002527568" DF="0.0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.18925743514851454" LOG_CI_START="-1.5871974438205523" LOG_EFFECT_SIZE="-0.6989700043360187" NO="2" P_CHI2="1.0" P_Z="0.12298899040634033" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="1.542348247614858">
<NAME>Respiratory failure within 48 hours of randomisation</NAME>
<DICH_DATA CI_END="1.5461706858829376" CI_START="0.025870365002527568" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.18925743514851454" LOG_CI_START="-1.5871974438205523" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="59" O_E="0.0" SE="1.043498389499902" STUDY_ID="STD-Mazzella-2001" TOTAL_1="18" TOTAL_2="18" VAR="1.0888888888888888" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.894602970670363" CI_START="0.010270623296195696" DF="0.0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="0.5904631907799176" LOG_CI_START="-1.9884031994519553" LOG_EFFECT_SIZE="-0.6989700043360187" NO="3" P_CHI2="1.0" P_Z="0.28803225758234696" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="1.062448244671742">
<NAME>Rescue by alternate NCPAP device</NAME>
<DICH_DATA CI_END="3.894602970670363" CI_START="0.010270623296195696" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5904631907799176" LOG_CI_START="-1.9884031994519553" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="60" O_E="0.0" SE="1.5148388832167146" STUDY_ID="STD-Mazzella-2001" TOTAL_1="18" TOTAL_2="18" VAR="2.2947368421052627" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Short binasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Nasopharyngeal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nasophar.</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="61" O_E="0.0" SE="0.0" STUDY_ID="STD-Mazzella-2001" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="69.09028858730673" CI_START="0.13026432779517255" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="1.839417006717952" LOG_CI_START="-0.8851744972786275" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.49243283298336993" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0" Z="0.6864445360982624">
<NAME>Pulmonary outcomes</NAME>
<GROUP_LABEL_1>Short binasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Nasopharyngeal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nasophar.</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Chronic lung disease (supplemental oxygen at 28 days)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="62" O_E="0.0" SE="0.0" STUDY_ID="STD-Mazzella-2001" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.09028858730673" CI_START="0.13026432779517255" DF="0.0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="1.839417006717952" LOG_CI_START="-0.8851744972786275" LOG_EFFECT_SIZE="0.47712125471966244" NO="2" P_CHI2="1.0" P_Z="0.49243283298336993" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="0.6864445360982624">
<NAME>Pneumothorax</NAME>
<DICH_DATA CI_END="69.09028858730673" CI_START="0.13026432779517255" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.839417006717952" LOG_CI_START="-0.8851744972786275" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="63" O_E="0.0" SE="1.6004385363930504" STUDY_ID="STD-Mazzella-2001" TOTAL_1="18" TOTAL_2="18" VAR="2.5614035087719293" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="155.85526140055754" CI_START="0.5197129649144479" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="2.1927214678811295" LOG_CI_START="-0.2842364490024796" LOG_EFFECT_SIZE="0.9542425094393249" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.13100681141354362" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0" Z="1.5101435016476166">
<NAME>Non-pulmonary outcomes</NAME>
<GROUP_LABEL_1>Short binasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Nasopharyngeal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nasophar.</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Intraventricular haemorrhage</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="64" O_E="0.0" SE="0.0" STUDY_ID="STD-Mazzella-2001" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="155.85526140055754" CI_START="0.5197129649144479" DF="0.0" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-006.04.02" LOG_CI_END="2.1927214678811295" LOG_CI_START="-0.2842364490024796" LOG_EFFECT_SIZE="0.9542425094393249" NO="2" P_CHI2="1.0" P_Z="0.13100681141354362" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="1.5101435016476166">
<NAME>Nasal trauma</NAME>
<DICH_DATA CI_END="155.8552614005574" CI_START="0.5197129649144481" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.192721467881129" LOG_CI_START="-0.2842364490024794" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="65" O_E="0.0" SE="1.4549773415168654" STUDY_ID="STD-Mazzella-2001" TOTAL_1="18" TOTAL_2="18" VAR="2.116959064327485" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Total days of respiratory support</NAME>
<GROUP_LABEL_1>Short binasal</GROUP_LABEL_1>
<GROUP_LABEL_2>Nasopharyngeal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sh. binasal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nasophar.</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6173047204335257" CI_START="-1.017304720433525" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.3" ORDER="66" SD_1="1.3" SD_2="1.2" SE="0.4169998667732268" STUDY_ID="STD-Mazzella-2001" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Hudson prong (short binasal) vs Argyle prong (short binasal) CPAP in preterm infants: broad inclusion criteria</NAME>
<DICH_OUTCOME CHI2="1.1884396973901722E-31" CI_END="0.7861285389610202" CI_START="0.2224522128263841" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4181818181818182" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="22" I2="100.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-0.10450643717001602" LOG_CI_START="-0.6527632697832859" LOG_EFFECT_SIZE="-0.37863485347665093" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0067860653261521044" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="46" WEIGHT="100.0" Z="2.7071643505783998">
<NAME>Nasal hyperaemia</NAME>
<GROUP_LABEL_1>Hudson prong</GROUP_LABEL_1>
<GROUP_LABEL_2>Argyle prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hudson prong</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Argyle prong</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7861285389610201" CI_START="0.2224522128263841" EFFECT_SIZE="0.41818181818181815" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="22" LOG_CI_END="-0.10450643717001608" LOG_CI_START="-0.6527632697832859" LOG_EFFECT_SIZE="-0.378634853476651" ORDER="67" O_E="0.0" SE="0.32204877739212556" STUDY_ID="STD-Rego-2002" TOTAL_1="50" TOTAL_2="46" VAR="0.10371541501976285" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5760934760971055" CI_START="0.6951341615232968" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3381818181818181" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.41096161777807655" LOG_CI_START="-0.1579313680915666" LOG_EFFECT_SIZE="0.12651512484325497" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.38334697678282015" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="46" WEIGHT="100.0" Z="0.8717459851023281">
<NAME>Nasal bleeding</NAME>
<GROUP_LABEL_1>Hudson prong</GROUP_LABEL_1>
<GROUP_LABEL_2>Argyle prong</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hudson prong</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Argyle prong</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5760934760971055" CI_START="0.6951341615232968" EFFECT_SIZE="1.3381818181818181" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.41096161777807655" LOG_CI_START="-0.1579313680915666" LOG_EFFECT_SIZE="0.12651512484325497" ORDER="68" O_E="0.0" SE="0.33417055596552536" STUDY_ID="STD-Rego-2002" TOTAL_1="50" TOTAL_2="46" VAR="0.11166996047430831" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>